Conditions: Healthy Volunteers
Keywords: Drug therapy
Allocation: RANDOMIZED | Intervention model: CROSSOVER
Enrollment: 15
Healthy volunteers: yes

Brief summary:
The purpose of this study is to determine the pharmacokinetic (PK) of a single oral dose of TAK-831 400 milligram (mg) in the fasted state and to estimate the effect of food on the PK of a single oral dose of TAK-831 400 mg when administered as tablet formulation in healthy participants.

Detailed description:
The drug being tested in this study is called TAK-831. TAK-831 is being tested in healthy participants under fasting and fed conditions in order to determine the effect of food on the PK of single oral dose of TAK-831 tablet formulation. The study will enroll approximately 16 participants. Participants will be randomly and equally assigned (by chance, like flipping a coin) to 1 of the 2 treatment sequences following as:

* TAK-831 400 mg Fasted + TAK-831 400 mg Fed
* TAK-831 400 mg Fed + TAK-831 400 mg Fasted All participants will be asked to take single oral dose of TAK-831 tablet at the same time on Day 1 of each Intervention Period. This single center trial will be conducted in the United States. The overall time to participate in this study is 23 days. Participants will visit the clinic on Day -1 and remained confined until Day 3 of Intervention Period 1 and 2. A washout period of minimum 7 days will be maintained between the doses in each Intervention Period. Participants will make 3 visits to the clinic on Days 4, 6 and 8 on each Intervention Period and will be contacted by telephone 14 days after the last dose of study drug (Day 23) for a follow-up assessment.

Arms:
arm 1: TAK-831 400 mg, film-coated tablets, orally under fasted state, once on Day 1 of Intervention Period 1, followed by 7 days washout period, further followed by TAK-831 400 mg, film-coated tablets, orally under fed state, once on Day 1 of Intervention Period 2. arm 2: TAK-831 400 mg, film-coated tablets, orally under fed state, once on Day 1 of Intervention Period 1, followed by 7 days washout period, further followed by TAK-831 400 mg, film-coated tablets, orally under fasted state, once on Day 1 of Intervention Period 2.

Interventions: intervention 1: TAK-831
Intervention descriptions: intervention 1: TAK-831 film-coated tablet.

Protocol document:
Prot_000.pdf: 
This may include, but is not limited to, redaction of the following: 

Named persons or organizations associated with the study.

•
Other information as needed to protect confidentiality of Takeda or partners, personal
information, or to otherwise protect the integrity of the clinical study.
Title: A Randomized, Open-Label, Single-Dose, 2-Period, Crossover Design, Phase 1 Study to 
Evaluate the Effect of Food on the Pharmacokinetics of TAK-831 T2 Tablet Formulation in 
Healthy Subjects
NCT Number: NCT03101293
Protocol Approve Date: 11 April 2016
Certain information within this protocol has been redacted (ie, specific content is masked 
irreversibly from view with a black bar) to protect either personally identifiable information or 
company confidential information. 
Proprietary information, such as scales or coding systems, which are considered confidential
information under prior agreements with license holder.


TITLE PAGE
PROTOCOL
A Randomized, Open-Label, Single-Dose, 2-Period, Crossover Design, Phase 1 Study to Evaluate 
the Effect of Food on the Pharmacokinetics of TAK-831 T2 Tablet Formulation in Healthy 
Subjects
Phase 1, Food Effect Study of TAK-831
Sponsor:
Takeda Development Center Americas, Inc.
One Takeda Parkway
Deerfield, IL 60015
Study Number:
TAK-831-1004
IND Number:
132,633
EudraCT Number:
Not applicable.
Compound:
TAK-831
Date:
11 April 2016
Version/Amendment 
Number:
Amendment 01
Amendment History:
Date
Amendment Number Amendment Type
Region
15 February 2017
Initial Version
11 April 2017
01
Not applicable
United States
CONFIDENTIAL PROPERTY OF TAKEDA
This document is a confidential communication of Takeda. Acceptance of this document constitutes the agreement by 
the recipient that no information contained herein will be published or disclosed without written authorization from 
Takeda except to the extent necessary to obtain informed consent from those persons to whom the drug may be 
administered. Furthermore, the information is only meant for review and compliance by the recipient, his or her staff, 
and applicable institutional review committee and regulatory agencies to enable conduct of the study.


TAK-831
Study No. TAK-831-1004
Page 2 of 82
Protocol Incorporating Amendment No. 01
11 April 2017
CONFIDENTIAL
1.0
ADMINISTRATIVE INFORMATION
1.1
Contacts
A separate contact information list will be provided to each site.
Contact Type / Role
Contact
Serious adverse event and pregnancy reporting
Takeda Pharmacovigilance
Takeda Development Center Americas, Inc.
Medical Monitor
(medical advice on protocol and compound)
Responsible Medical Officer (carries overall 
responsibility for the conduct of the study)
PPD


TAK-831
Study No. TAK-831-1004
Page 3 of 82
Protocol Incorporating Amendment No. 01
11 April 2017
CONFIDENTIAL
1.2
Approval
REPRESENTATIVES OF TAKEDA
This study will be conducted with the highest respect for the individual participants in accordance 
with the requirements of this clinical study protocol and also in accordance with the following:
!
The ethical principles that have their origin in the Declaration of Helsinki.
!
International Conference on Harmonisation E6 Good Clinical Practice Consolidated
Guideline.
!
All applicable laws and regulations, including, without limitation, data privacy laws, clinical
trial disclosure laws, and regulations.
SIGNATURES
The signature of the responsible Takeda medical officer and other signatories, as applicable, can 
be found on the signature page.
Electronic signatures may be found on the last page of this document.
PPD
PPD
PPD
PPD


TAK-831
Study No. TAK-831-1004
Page 4 of 82
Protocol Incorporating Amendment No. 01
11 April 2017
CONFIDENTIAL
1.3
Protocol Amendment 01 Summary of Changes 
Rationale for Amendment No. 01
This document describes the changes in reference to the Protocol Incorporating Amendment 
No. 01.
The primary purpose of this amendment is to update the protocol regarding additional ECG time 
points at the expected Cmax of the TAK-831 tablet, to add the investigator’s clinical judgment as a 
criterion for withdrawing a subject due to liver function test abnormalities, and to correct 
inconsistences in the description of contraception requirements. Other minor changes in 
procedures are proposed. Minor grammatical and editorial changes are included for clarification 
purposes only. For specific descriptions of text changes and where the changes are located, see 
Appendix E.
Changes in Amendment No. 1
1. Addition of investigator’s clinical judgment as criterion for withdrawing subject due to liver
function test abnormalities.
2. Correction of inconsistences in the description of contraception requirements.
3. Addition of extra ECG timepoints.


TAK-831
Study No. TAK-831-1004
Page 5 of 82
Protocol Incorporating Amendment No. 01
11 April 2017
CONFIDENTIAL
INVESTIGATOR AGREEMENT
I confirm that I have read and that I understand this protocol, the Investigator’s Brochure, package 
insert, and any other product information provided by the sponsor. I agree to conduct this study in 
accordance with the requirements of this protocol and also to protect the rights, safety, privacy, 
and well-being of study subjects in accordance with the following:

The ethical principles that have their origin in the Declaration of Helsinki.

International Conference on Harmonisation, E6 Good Clinical Practice: Consolidated
Guideline.

All applicable laws and regulations, including, without limitation, data privacy laws and
regulations.

Regulatory requirements for reporting serious adverse events defined in Section 10.2 of this
protocol.

Terms outlined in the study site agreement.

Responsibilities of the Investigator (Appendix B).
I further authorize that my personal information may be processed and transferred in accordance 
with the uses contemplated in Appendix D of this protocol.
Signature of Investigator
Date
Investigator Name (print)
Investigator’s Title
Location of Facility (City, State)
Location of Facility (Country)


TAK-831
Study No. TAK-831-1004
Page 6 of 82
Protocol Incorporating Amendment No. 01
11 April 2017
CONFIDENTIAL
TABLE OF CONTENTS
1.0
ADMINISTRATIVE INFORMATION ...........................................................................2
1.1
Contacts.....................................................................................................................2
1.2
Approval....................................................................................................................3
1.3
Protocol Amendment 01 Summary of Changes ..........................................................4
2.0
STUDY SUMMARY ....................................................................................................11
3.0
STUDY REFERENCE INFORMATION ......................................................................14
3.1
Study-Related Responsibilities.................................................................................14
3.2
Principal Investigator...............................................................................................14
3.3
List of Abbreviations ...............................................................................................15
3.4
Corporate Identification...........................................................................................16
4.0
INTRODUCTION.........................................................................................................17
4.1
Background .............................................................................................................17
4.2
Rationale for the Proposed Study.............................................................................18
5.0
STUDY OBJECTIVES AND ENDPOINTS..................................................................20
5.1
Objectives................................................................................................................20
5.1.1
Primary Objectives.............................................................................................20
5.1.2
Secondary Objective ..........................................................................................20
5.1.3
Exploratory Objectives.......................................................................................20
5.2
Endpoints.................................................................................................................20
5.2.1
Primary Endpoints: ............................................................................................20
5.2.2
Secondary Endpoint ...........................................................................................20
5.2.3
Exploratory Endpoints .......................................................................................20
6.0
STUDY DESIGN AND DESCRIPTION.......................................................................22
6.1
Study Design ...........................................................................................................22
6.2
Justification for Study Design, Dose, and Endpoints ................................................23
6.3
Premature Termination or Suspension of Study or Investigational Site.....................24
6.3.1
Criteria for Premature Termination or Suspension of the Study..........................24
6.3.2
Criteria for Premature Termination or Suspension of Investigational Sites .........25
6.3.3
Procedures for Premature Termination or Suspension of the Study or the 
Participation of Investigational Site....................................................................25
7.0
SELECTION AND DISCONTINUATION/WITHDRAWAL OF SUBJECTS..............26
7.1
Inclusion Criteria .....................................................................................................26
7.2
Exclusion Criteria ....................................................................................................26
7.3
Excluded Medications, Supplements, Dietary Products............................................28


TAK-831
Study No. TAK-831-1004
Page 7 of 82
Protocol Incorporating Amendment No. 01
11 April 2017
CONFIDENTIAL
7.4
Diet, Fluid, Activity Control ....................................................................................29
7.5
Criteria for Discontinuation or Withdrawal of a Subject...........................................30
7.6
Procedures for Discontinuation or Withdrawal of a Subject......................................31
8.0
CLINICAL STUDY MATERIAL MANAGEMENT.....................................................32
8.1
Study Drug and Materials ........................................................................................32
8.1.1
Dosage Form, Manufacturing, Packaging, and Labeling.....................................32
8.1.1.1 Study Drug...................................................................................................32
8.1.1.2 Ancillary Materials.......................................................................................32
8.1.1.3 Sponsor-Supplied Drug ................................................................................32
8.1.2
Storage...............................................................................................................32
8.1.3
Dose and Regimen .............................................................................................32
8.1.4
Overdose............................................................................................................33
8.2
Study Drug Assignment and Dispensing Procedures ................................................33
8.3
Randomization Code Creation and Storage..............................................................33
8.4
Accountability and Destruction of Sponsor-Supplied Drugs.....................................34
9.0
STUDY PLAN ..............................................................................................................36
9.1
Study Procedures.....................................................................................................36
9.1.1
Informed Consent Procedure..............................................................................36
9.1.1.1 Pharmacogenomics Informed Consent Procedure.........................................36
9.1.2
Demographics, Medical History, and Medication History Procedure..................36
9.1.3
Physical Examination Procedure ........................................................................36
9.1.4
Weight, Height and BMI....................................................................................37
9.1.5
Vital Sign Procedure..........................................................................................37
9.1.6
Documentation of Concomitant Medications......................................................37
9.1.7
Documentation of Concurrent Medical Conditions.............................................37
9.1.8
Procedures for Clinical Laboratory Samples.......................................................38
9.1.9
Contraception and Pregnancy Avoidance Procedure...........................................39
9.1.9.1 Male Subjects and Their Female Partners.....................................................39
9.1.9.2 Female Subjects and Their Male Partners.....................................................39
9.1.9.3 Definitions and Procedures for Contraception and Pregnancy Avoidance .....40
9.1.10 Pregnancy ..........................................................................................................42
9.1.11 ECG Procedure..................................................................................................42
9.1.12 PGx Sample Collection......................................................................................43
9.1.13 PK Sample Collection........................................................................................43
9.1.13.1
Collection of Blood for PK Sampling .....................................................43


TAK-831
Study No. TAK-831-1004
Page 8 of 82
Protocol Incorporating Amendment No. 01
11 April 2017
CONFIDENTIAL
9.1.13.2
Bioanalytical Methods............................................................................44
9.1.14 PK Parameters ...................................................................................................44
9.1.15 PD Sample Collection........................................................................................44
9.1.16 PD Parameters ...................................................................................................45
9.1.17 Documentation of Screen Failure .......................................................................45
9.1.18 Documentation of Randomization......................................................................46
9.1.19 C-SSRS..............................................................................................................46
9.2
Monitoring Subject Treatment Compliance..............................................................46
9.3
Schedule of Observations and Procedures................................................................46
9.3.1
Screening...........................................................................................................46
9.3.2
Study Entrance/Randomization ..........................................................................46
9.3.3
Treatment Periods 1 and 2..................................................................................47
9.3.4
Study Exit ..........................................................................................................47
9.3.5
Early Termination..............................................................................................47
9.3.6
Follow-up Visit/Telephone Call .........................................................................47
9.4
Biological Sample Retention and Destruction ..........................................................47
9.5
Blood Volume .........................................................................................................48
10.0
PRETREATMENT EVENTS AND ADVERSE EVENTS ............................................49
10.1
Definitions...............................................................................................................49
10.1.1 PTEs..................................................................................................................49
10.1.2 AEs....................................................................................................................49
10.1.3 Additional Points to Consider for PTEs and AEs................................................49
10.1.4 SAEs..................................................................................................................51
10.1.5 Intensity of PTEs and AEs .................................................................................52
10.1.6 Relationship of AEs to Study Drug ....................................................................52
10.1.7 Relationship to Study Procedures.......................................................................52
10.1.8 Start Date...........................................................................................................53
10.1.9 Stop Date...........................................................................................................53
10.1.10
Frequency ....................................................................................................53
10.1.11
Action Concerning Study Drug ....................................................................53
10.1.12
Outcome.......................................................................................................53
10.2
Procedures...............................................................................................................54
10.2.1 Collection and Reporting of AEs........................................................................54
10.2.1.1
PTE and AE Collection Period ...............................................................54
10.2.1.2
PTE and AE Reporting ...........................................................................54


TAK-831
Study No. TAK-831-1004
Page 9 of 82
Protocol Incorporating Amendment No. 01
11 April 2017
CONFIDENTIAL
10.2.2 Collection and Reporting of SAEs......................................................................55
10.2.3 Reporting of Abnormal LFTs.............................................................................55
10.3
Follow-up of SAEs ..................................................................................................55
10.3.1 Safety Reporting to Investigators, IRBs, and Regulatory Authorities..................56
11.0
STUDY-SPECIFIC COMMITTEES .............................................................................57
12.0
DATA HANDLING AND RECORDKEEPING............................................................58
12.1
eCRFs......................................................................................................................58
12.2
Record Retention .....................................................................................................58
13.0
STATISTICAL METHODS..........................................................................................60
13.1
Statistical and Analytical Plans ................................................................................60
13.1.1 Analysis Sets......................................................................................................60
13.1.2 Analysis of Demographics and Other Baseline Characteristics ...........................60
13.1.3 PK Analysis .......................................................................................................61
13.1.3.1
TAK-831 Concentrations in Plasma........................................................61
13.1.3.2
Plasma PK Parameters............................................................................61
13.1.4 PD Analysis .......................................................................................................61
13.1.4.1
D-Serine and L-Serine Concentrations in Plasma....................................61
13.1.4.2
Plasma PD Parameters............................................................................61
13.1.5 Safety Analysis ..................................................................................................62
13.1.5.1
AEs ........................................................................................................62
13.1.5.2
Clinical Laboratory Evaluations..............................................................62
13.1.5.3
Vital Signs..............................................................................................62
13.1.5.4
ECGs......................................................................................................62
13.1.5.5
Other Variables ......................................................................................62
13.2
Interim Analysis and Criteria for Early Termination ................................................62
13.3
Determination of Sample Size..................................................................................63
14.0
QUALITY CONTROL AND QUALITY ASSURANCE...............................................64
14.1
Study-Site Monitoring Visits ...................................................................................64
14.2
Protocol Deviations..................................................................................................64
14.3
Quality Assurance Audits and Regulatory Agency Inspections ................................65
15.0
ETHICAL ASPECTS OF THE STUDY........................................................................66
15.1
IRB Approval ..........................................................................................................66
15.2
Subject Information, Informed Consent, and Subject Authorization .........................67
15.3
Subject Confidentiality ............................................................................................68
15.4
Publication, Disclosure, and Clinical Trial Registration Policy.................................68


TAK-831
Study No. TAK-831-1004
Page 10 of 82
Protocol Incorporating Amendment No. 01
11 April 2017
CONFIDENTIAL
15.4.1 Publication and Disclosure.................................................................................68
15.4.2 Clinical Trial Registration..................................................................................69
15.4.3 Clinical Trial Results Disclosure ........................................................................69
15.5
Insurance and Compensation for Injury....................................................................69
16.0
REFERENCES..............................................................................................................70
LIST OF IN-TEXT TABLES
Table 6.a
Study Treatment Sequences ...............................................................................22
Table 7.a
Excluded Medications, Supplements, and Dietary Products................................29
Table 8.a
Study Drug Supplies per Treatment Period.........................................................33
Table 9.a
Clinical Laboratory Tests...................................................................................38
Table 9.b
Collection of Blood Samples for PK Analysis ....................................................44
Table 9.c
Plasma PK Parameters .......................................................................................44
Table 9.d
Collection of Blood Samples for PD Analysis ....................................................45
Table 9.e
Plasma PD Parameters .......................................................................................45
Table 9.f
Approximate Blood Volume ..............................................................................48
Table 10.a
Takeda Medically Significant AE List................................................................52
Table 14.a
Windows for PK and PD Blood Sample Collection............................................65
LIST OF IN-TEXT FIGURES
Figure 6.a
Schematic of Study Design ................................................................................23
LIST OF APPENDICES
Appendix A
Schedule of Study Procedures............................................................................72
Appendix B
Responsibilities of the Investigator.....................................................................74
Appendix C
Elements of the Subject Informed Consent.........................................................76
Appendix D
Investigator Consent to Use of Personal Information..........................................79
Appendix E
Detailed Description of Amendments to Text.....................................................80


TAK-831
Study No. TAK-831-1004
Page 11 of 82
Protocol Incorporating Amendment No. 01
11 April 2017
CONFIDENTIAL
2.0
STUDY SUMMARY
Name of Sponsor:
Takeda Development Center Americas, Inc.
Compound:
TAK-831
Title of Protocol: A Randomized, Open-Label, 
Single-Dose, 2-Period, Crossover Design, Phase 1 Study to 
Evaluate the Effect of Food on the Pharmacokinetics of 
TAK-831 T2 Tablet Formulation in Healthy Subjects
IND No.: 132,633
EudraCT No.: Not 
applicable.
Study Number: TAK-831-1004
Phase: 1
Study Design:
TAK-831-1004 is a phase 1, randomized, open-label, single-dose, 2-period crossover study designed to characterize 
the pharmacokinetics (PK) of TAK-831 400 mg and assess the effect of food on the bioavailability of TAK-831 
400 mg, when administered as four 100 mg oral tablets of the T2 formulation in healthy male and female adult 
subjects.
At Check-in (Day -1) of Period 1, 16 healthy male and female subjects, aged 18 to 55 years, inclusive, who meet the 
study entry criteria will be enrolled in the study. On Day 1 of Period 1, eligible subjects will be randomly assigned in 
a 1:1 ratio to 1 of 2 treatment sequences, which will define the order in which they will receive the TAK-831 regimens 
in Periods 1 and 2 (Table 1). Dosing between periods will be separated by a washout interval of ≥7 days.
Table 1. Study Treatment Sequences
Treatment Sequence
Number of Subjects
Regimen
Period 1
Period 2
1
8
A
B
2
8
B
A
Regimen A=a single oral dose of 4 TAK-831 100 mg tablets (T2 formulation; total dose 400 mg) administered on Day 1 with water; 
Regimen B=a single oral dose of 4 TAK-831 100 mg tablets (T2 formulation; total dose 400 mg) administered on Day 1, 
15 minutes after starting ingestion of Ensure Plus. For both regimens, subjects will fast for ≥10 hours overnight before dosing.
The study will include a Screening Period (Days -28 to -2), 2 treatment periods, and a Follow-up Phone Call 
(14±2 days after last dose of study drug). In each period, subjects will be admitted to the clinic on Day -1 (Check-in) 
and will remain confined to the clinic until completion of study procedures on the morning of Day 3. Subjects will 
return to the clinic for study assessments on Days 4, 6, and 8 in each period. Subjects will receive a single dose of 
TAK-831 on Day 1 of each period. Blood samples will be collected over 72 hours postdose to measure plasma 
concentrations of TAK-831 for PK assessments in each period.
 
 
Safety will be evaluated throughout the study. The schematic of the study design is 
presented in Table 2.
Table 2. Schematic of Study Design
Screening
Treatment Periods 1 and 2 
Study Exit
Follow-up 
(a)
Check-in and Predose
Assessments
Dosing and
Study Assessments
PK, PD, and Safety
Assessments
Days
-28 to -2
Day -1
Day 1
Days
1 to 3 
Days
4 to 8 
Period 2 Day 8
(Study Day 16)
Study
Day 23 (±2)
Confinement
(a) The Follow-up Visit will occur (14 days after the last dose of study drug) by telephone unless abnormal, clinically significant 
findings were observed at Study Exit. In these cases, subjects will be brought back into the clinic for re-evaluation at the 
investigator’s discretion.
CCI
CCI


TAK-831
Study No. TAK-831-1004
Page 12 of 82
Protocol Incorporating Amendment No. 01
11 April 2017
CONFIDENTIAL
Primary Objectives

To determine the PK of a single oral dose of TAK-831 400 mg in the fasted state and to estimate the effect of food 
on the PK of a single oral dose of TAK-831 400 mg when administered as the new T2 tablet formulation in 
healthy subjects.
Secondary Objective

To evaluate the safety and tolerability of a single oral dose of TAK-831 400 mg in healthy subjects in the fed and 
fasted states.
Subject Population: Healthy male and female subjects aged 18 to 55 years, inclusive. Women of childbearing 
potential will be excluded.
Number of Subjects:
Per treatment sequence: 8 healthy subjects 
Estimated total: 16 healthy subjects
Number of Sites:
1 in the United States
Dose Level:
TAK-831 400 mg (as four 100 mg T2 tablets)
Route of Administration:
Oral 
Duration of Treatment:
Single dose in each of 2 treatment periods.
Period of Evaluation:
8 days per period, with a washout interval ≥7 days 
between the dose in Period 1 and Period 2.
Main Criteria for Inclusion: 

The subject is a healthy adult male or healthy adult female of nonchildbearing potential. 

The subject is aged 18 to 55 years, inclusive, at the time of informed consent and first study drug dose. 

The subject weighs ≥45 kg and has a body mass index between 18.0 and 30.0 kg/m2, inclusive, at Screening.
Main Criteria for Exclusion: 

If female, the subject is of childbearing potential (eg, premenopausal, not sterilized).

The subject has current or recent (within 6 months) gastrointestinal disease that would be expected to influence 
the absorption of drugs (ie, a history of malabsorption, esophageal reflux, peptic ulcer disease, erosive 
esophagitis, frequent [more than once per week] occurrence of heartburn, or any surgical intervention).

The subject has a lifetime history of suicidal ideation as evidenced by a score ≥3 in the Columbia-Suicide Severity 
Rating Scale at Screening or Baseline, or a history of suicidal behavior. 

The subject has a known hypersensitivity to any component of the formulation of TAK-831 or Ensure Plus.

The subject has any dietary restrictions or preferences that may interfere with the conduct of the study.
Main Criteria for Evaluation and Analyses:
Primary Endpoints:
The following PK parameters of TAK-831 derived for each period:

Maximum observed plasma concentration (Cmax).

Area under the plasma concentration-time curve from time 0 to time of the last quantifiable concentration 
(AUClast).

Area under the plasma concentration-time curve from time 0 to infinity (AUC∞).
Secondary Endpoints

Percentage of subjects who experience at least 1 treatment-emergent adverse event (TEAE).


TAK-831
Study No. TAK-831-1004
Page 13 of 82
Protocol Incorporating Amendment No. 01
11 April 2017
CONFIDENTIAL
Statistical Considerations:
PK:
For each regimen, TAK-831 plasma concentrations and PK parameter estimates will be summarized using descriptive 
statistics (N, mean, median, SD, percent coefficient of variation [%CV], minimum, maximum). In addition, geometric 
means will be calculated for Cmax and area under the plasma concentration-time curves (AUCs). Individual subject 
plasma concentration and PK parameter data also will be listed.
Analysis of variance models will be performed on TAK-831 lnCmax and lnAUCs. The model will include sequence, 
period, and regimen as fixed factors and subject-within-sequence as a random factor. Pairwise comparisons between 
the test regimen (Regimen B: fed state) and the reference regimen (Regimen A: fasted state) will be made and the 
2-sided 90% CIs for the ratio of the central values for Cmax and AUCs between regimens (Test: Reference) will be 
constructed to estimate the effect of food on TAK-831 PK.
Safety:
TEAEs will be presented in the data listings and summarized for each regimen by system organ class and preferred 
term (using the Medical Dictionary for Regulatory Activities) with descriptive statistics (N and percentage of 
subjects).
Sample Size Justification: With a sample size of 16 subjects (8 subjects per treatment sequence), allowing for a 
maximum of 2 dropouts, a 2-sided 90% CI for the difference in the paired means of the lnCmax will extend 0.23 from 
the observed mean. Assuming a point estimate of the food effect of 2 (observed ratio of fed vs fasting Cmax=2), which 
means food increases Cmax by 100%, this should lead to a lower bound of the 90% CI of 1.589 (58.9% increase) and an 
upper bound of the 90% CI of 2.517 (151.7% increase) for the ratios of the Cmax central values (fed/fast). In addition, 
when a central value ratio of 1 is observed, the 90% CI should be approximately (-0.79, 1.26). This calculation also 
assumes the intrasubject %CV for Cmax is 37.5%, which is estimated from Study TAK-831-1001 (Part 4).


TAK-831
Study No. TAK-831-1004
Page 14 of 82
Protocol Incorporating Amendment No. 01
11 April 2017
CONFIDENTIAL
3.0
STUDY REFERENCE INFORMATION
3.1
Study-Related Responsibilities
The sponsor will perform all study-related activities with the exception of those identified in the 
Study-Related Responsibilities template. The vendors identified for specific study-related 
activities will perform these activities in full or in partnership with the sponsor.
3.2
Principal Investigator
PPD


TAK-831
Study No. TAK-831-1004
Page 15 of 82
Protocol Incorporating Amendment No. 01
11 April 2017
CONFIDENTIAL
3.3
List of Abbreviations
Term
Definition
%CV
percent coefficient of variation
AE
adverse event
ALT
alanine aminotransferase
AST
aspartate aminotransferase
AUC
area under the plasma concentration-time curve
AUC∞
area under the plasma concentration-time curve from time 0 to infinity
AUClast
area under the plasma concentration-time curve from time 0 to last quantifiable concentration
AUEClast
area under the effect-time curve from time 0 to the last scheduled postdose time point
BMI
body mass index
CFR
Code of Federal Regulations
CHMP
Committee for Medicinal Products for Human Use
CL/F
apparent clearance after extravascular administration
Cmax
maximum observed plasma concentration
CNS
central nervous system
C-SSRS
Columbia-Suicide Severity Rating Scale
DAO
D-amino acid oxidase
ECG
electrocardiogram
eCRF
electronic case report form
Emax
maximum observed effect
FDA
Food and Drug Administration
FRDA
Friedreich ataxia
FSH
follicle-stimulating hormone
GCP
Good Clinical Practice
GGT
-glutamyl transferase
HBsAg
hepatitis B surface antigen
hCG
human chorionic gonadotrophin
HCV
hepatitis C virus
HIV
human immunodeficiency virus
ICH
International Conference on Harmonisation
INR
international normalized ratio
IRB
institutional review board
LFT
liver function test
MedDRA
Medical Dictionary for Regulatory Activities
MHRA
Medicines and Healthcare products Regulatory Agency
NMDA
N-methyl-D-aspartate
OTC
over-the-counter
PD
pharmacodynamics(s)
PET
positron emission tomography


TAK-831
Study No. TAK-831-1004
Page 16 of 82
Protocol Incorporating Amendment No. 01
11 April 2017
CONFIDENTIAL
Term
Definition
PGx
pharmacogenomics(s)
PK
pharmacokinetic(s)
PT
preferred term
PTE
pretreatment event
QTcF
QT interval with Fridericia correction method 
SAE
serious adverse event
SAP
statistical analysis plan
SOC
system organ class
SRD
single rising dose(s)
t1/2z
terminal disposition phase half-life
TEAE
treatment-emergent adverse event
time to Emax
time to reach maximum observed effect
tmax
time of first occurrence of Cmax
ULN
upper limit of normal
Vz/F
apparent volume of distribution during the terminal disposition phase after extravascular 
administration
3.4
Corporate Identification
Takeda
Takeda Development Center Americas and Europe


TAK-831
Study No. TAK-831-1004
Page 17 of 82
Protocol Incorporating Amendment No. 01
11 April 2017
CONFIDENTIAL
4.0
INTRODUCTION
4.1
Background
Ataxia manifests as impaired coordination of muscle movements. It is a nonspecific clinical 
manifestation indicative of dysfunction in the parts of the central nervous system (CNS) that 
coordinate movement, such as the cerebellum. The cerebellum is one of the key CNS structures 
responsible for collating neural information and using it in the coordination of smoothly ongoing 
movements, as well as participating in motor planning [1]. Patients with ataxia have trouble 
regulating the force, range, direction, velocity, and rhythm of muscle contractions, resulting in a 
characteristic type of irregular, uncoordinated movement that can manifest itself in many possible 
ways, such as asthenia, asynergy, delayed reaction time, and dyschronometria [1]. Patients also 
display instability of gait, difficulty with eye movements, dysarthria, dysphagia, hypotonia, 
dysmetria, and dysdiadochokinesia (impaired ability to perform rapid, alternating movements). 
These difficulties can affect employability, lead to disability, increase caregiver burden, and 
significantly reduce a person’s health-related quality of life [2]. 
There are numerous types of ataxias, many genetically mediated and others idiopathic. Friedreich 
ataxia (FRDA) is the most common form of hereditary ataxia in the Western world, with an overall 
Caucasian prevalence of 1 in 50,000 people [3-5]. The number of individuals affected with FRDA 
at any given time in the United States is approximately 9000 [6]. In FRDA, a 
guanine-adenine-adenine (GAA) trinucleotide repeat expansion mutation in intron 1 of the 
frataxin gene (FXN) results in drastically reduced levels of the frataxin protein [5,7], which, in 
turn, leads to mitochondrial dysfunction, neurodegeneration, cardiomyopathy, diabetes mellitus, 
and skeletal deformities [8,9]. This disorder has a sensory ataxia component secondary to 
involvement of the dorsal root ganglia and spinocerebellar tracts, with loss of proprioceptive 
function and sensory neuropathy, as well as gradual decreases in sensory function that lead to 
visual and hearing impairments [10]. There is progressive destruction of the cerebellar dentate 
nucleus and the corticospinal tract [10].
Various compounds are under investigation [11,12]. However, there is currently no cure or 
approved effective treatment for any of the hereditary ataxias [13]. Thus, there is a great need to 
identify and develop effective therapies for patient populations with ataxia.
TAK-831 is a novel, highly selective and potent, small molecule inhibitor of D-amino acid oxidase 
(DAO), a peroxisomal enzyme active toward neutral D-amino acids, under development by 
Takeda for the treatment of various CNS disorders, including FRDA. In animal models, TAK-831 
CCI


TAK-831
Study No. TAK-831-1004
Page 18 of 82
Protocol Incorporating Amendment No. 01
11 April 2017
CONFIDENTIAL
Additional information regarding the nonclinical pharmacology, pharmacokinetics (PK), and 
toxicology of TAK-831 is provided in the current Investigator’s Brochure.
Two phase 1 studies have been conducted with TAK-831 in healthy subjects. The first study 
(TAK-831-1001) characterized the PK and pharmacodynamics (PD) of single-rising doses (SRD) 
(10 to 750 mg) and multiple-rising doses (30 to 400 mg) of a TAK-831 oral suspension, the 
relative bioavailability of an oral tablet (T1 formulation; 100 mg), and the effect of food (high-fat 
meal) on the tablet (100 mg). TAK-831 was absorbed rapidly following single and multiple doses 
of the oral suspension, with median time of first occurrence of Cmax (tmax) values of 0.25 to 1 hour 
(range 0.17 to 2 hours). Exposure was generally dose dependent, with low intersubject variability 
(percent coefficient of variation [%CV] <40%). Corresponding mean terminal disposition phase 
half-life (t1/2z) values ranged from 6 to 23 hours. Oral administration of a TAK-831 100 mg tablet 
with food increased TAK-831 exposure approximately 2-fold relative to administration without 
food. In the fasted state, exposure from the tablet was approximately 2-fold lower than that from 
the oral suspension. After single and multiple doses of TAK-831, changes from Baseline in 
D-serine area under the effect curve from time 0 to 24 hours (AUEC24) were dose dependent. 
The second study (TAK-831-1003) used positron emission tomography (PET) to investigate brain 
DAO enzyme occupancy by TAK-831 after a single oral dose (100 to 500 mg) in healthy male 
subjects. The results demonstrated that the tracer crossed the blood brain barrier in humans with 
highest uptake in the cerebellum and brainstem and low uptake in the frontal cortex, a distribution 
consistent with DAO distribution in rodents [15]. Administration of TAK-831 blocked uptake of 
the tracer indicating that the TAK-831 binding to brain DAO is specific. Using a multilinear 
analysis-1 model [16], the in vivo TAK-831 plasma concentration at 50% occupancy (EC50) for 
brain DAO was estimated to be 12.7 ng/mL (95% CI=2.3, 23.1). In conclusion, this study 
demonstrates that TAK-831 accesses the DAO enzyme in the brain and displays high target 
occupancy at tested doses that have been shown to be safe in Study TAK-831-1001.
In both phase 1 studies (TAK-831-1001, TAK-831-1003), TAK-831 was generally safe and well 
tolerated at the doses administered in healthy subjects. No deaths, serious adverse events (SAEs), 
or treatment-emergent adverse events (TEAEs) leading to discontinuation were reported in either 
study. The most frequently reported TEAEs in Study TAK-831-1001 were postural dizziness and 
headache. The rate of postural dizziness in subjects receiving TAK-831 did not markedly differ 
from the rate observed in subjects receiving placebo. In Study TAK-831-1003 (PET occupancy, 
single dose), the most common TEAEs overall were related to the catheter site (pain, bruise, or 
hematoma); the remaining TEAEs were consistent with those reported in Study TAK-831-1001. 
No concerning trends in clinical laboratory, electrocardiogram (ECG), or vital sign data were 
observed in either study.
4.2
Rationale for the Proposed Study
A new T2 oral tablet formulation of TAK-831 has been developed and is planned for use in future 
clinical studies. The purpose of the current study is to characterize the PK of a single 400 mg dose 
of the TAK-831 T2 tablet formulation (given the stability limitations of the current T1 tablet 


TAK-831
Study No. TAK-831-1004
Page 19 of 82
Protocol Incorporating Amendment No. 01
11 April 2017
CONFIDENTIAL
formulation), and to evaluate the effect of food on the PK of a single 400 mg dose of the T2 tablet 
formulation (given the positive food effect observed with the current T1 tablet formulation).


TAK-831
Study No. TAK-831-1004
Page 20 of 82
Protocol Incorporating Amendment No. 01
11 April 2017
CONFIDENTIAL
5.0
STUDY OBJECTIVES AND ENDPOINTS
5.1
Objectives
5.1.1
Primary Objectives
!
To determine the PK of a single oral dose of TAK-831 400 mg in the fasted state and to 
estimate the effect of food on the PK of a single oral dose of TAK-831 400 mg when 
administered as the T2 tablet formulation in healthy subjects.
5.1.2
Secondary Objective
!
To evaluate the safety and tolerability of a single oral dose of TAK-831 400 mg in healthy 
subjects in the fed and fasted states.
5.1.3
Exploratory Objectives
5.2
Endpoints
5.2.1
Primary Endpoints:
The following PK parameters of TAK-831 derived for each regimen:
!
Maximum observed plasma concentration (Cmax).
!
Area under the plasma concentration-time curve from time 0 to time of the last quantifiable 
concentration (AUClast).
!
Area under the plasma concentration-time curve from time 0 to infinity (AUC∞).
5.2.2
Secondary Endpoint
!
Percentage of subjects who experience at least 1 TEAE.
5.2.3
Exploratory Endpoints
CCI
CCI


TAK-831
Study No. TAK-831-1004
Page 21 of 82
Protocol Incorporating Amendment No. 01
11 April 2017
CONFIDENTIAL
The following PK parameters for TAK-831 for each regimen:
!
tmax.
!
t1/2z.
!
CL/F.
!
Vz/F.
CCI


TAK-831
Study No. TAK-831-1004
Page 22 of 82
Protocol Incorporating Amendment No. 01
11 April 2017
CONFIDENTIAL
6.0
STUDY DESIGN AND DESCRIPTION
6.1
Study Design
TAK-831-1004 is a phase 1, randomized, open-label, single-dose, 2-period crossover study 
designed to characterize the PK of TAK-831 400 mg and assess the effect of food on the 
bioavailability of TAK-831 400 mg, when administered as four 100 mg oral tablets of the T2 
formulation in healthy male and female adult subjects.
At Check-in (Day -1) of Period 1, 16 healthy male and female subjects, aged 18 to 55 years, 
inclusive, who meet the study entry criteria will be enrolled in the study. On Day 1 of Period 1, 
eligible subjects will be randomly assigned in a 1:1 ratio to 1 of 2 treatment sequences, which will 
define the order in which they will receive the TAK-831 regimens in Periods 1 and 2 (Table 6.a). 
Dosing between periods will be separated by a washout interval of ≥7 days.
Table 6.a
Study Treatment Sequences
Treatment Sequence
Number of Subjects
Regimen
Period 1
Period 2
1
8
A
B
2
8
B
A
Regimen A=a single oral dose of 4 TAK-831 100 mg tablets (T2 formulation; total dose 400 mg) administered on Day 1 with water; 
Regimen B=a single oral dose of 4 TAK-831 100 mg tablets (T2 formulation; total dose 400 mg) administered on Day 1, 
15 minutes after starting ingestion of Ensure Plus. For both regimens, subjects will fast for ≥10 hours overnight before dosing.
The study will include a Screening Period (Days -28 to -2), 2 treatment periods, and a Follow-up 
Phone Call (14±2 days after last dose of study drug). In each period, subjects will be admitted to 
the clinic on Day -1 (Check-in) and will remain confined to the clinic until completion of study 
procedures on the morning of Day 3. Subjects will return to the clinic for study assessments on 
Days 4, 6, and 8 in each period. Subjects will receive a single dose of TAK-831 on Day 1 of each 
period. Blood samples will be collected over 72 hours postdose to measure plasma concentrations 
of TAK-831 for PK assessments in each period.
 
 Safety will be evaluated throughout the study.
A schematic of the study design is shown in Figure 6.a. A schedule of study procedures is provided 
in Appendix A.
CCI
CCI


TAK-831
Study No. TAK-831-1004
Page 23 of 82
Protocol Incorporating Amendment No. 01
11 April 2017
CONFIDENTIAL
Figure 6.a
Schematic of Study Design
Screening
Treatment Periods 1 and 2 
Study Exit
Follow-up 
(a)
Check-in and Predose
Assessments
Dosing and
Study Assessments
PK, PD, and Safety
Assessments
Days
-28 to -2
Day -1
Day 1 (b)
Days
1 to 3 
Days
4 to 8 
Period 2 Day 8
(Study Day 16)
Study 
Day 23 (±2)
Confinement (c)
(a) The Follow-up Visit will occur (14 days after the last dose of study drug) by telephone unless abnormal, clinically significant 
findings were observed at Study Exit. In these cases, subjects will be brought back into the clinic for re-evaluation at the 
investigator’s discretion.
(b) Subjects will be randomly assigned to 1 of 2 treatment sequences before dosing on Day 1 of Period 1. A washout interval of 
≥7 days will separate the dose in Period 1 from the dose in Period 2.
(c) Subjects will be discharged from the clinic after the Day 3 study assessments have been completed and will return to the clinic 
on Days 4, 6, and 8 for study assessments.
The end of the study is defined as the date the last subject completes the Follow-up Phone Call.
6.2
Justification for Study Design, Dose, and Endpoints
This phase 1 food-effect study is designed in accordance with the Bioavailability and 
Bioequivalence Studies Submitted in NDAs or INDs—General Considerations Guidance for 
Industry from the Food and Drug Administration (FDA), the Food-Effect Bioavailability and Fed 
Bioequivalence Studies Guidance for Industry from the FDA [17], the Guideline on the 
Investigation of Bioequivalence from the Committee for Medicinal Products for Human Use 
(CHMP) [18], and the Guideline on the Investigation of Drug Interactions from the CHMP (which 
includes food-effect studies) [19].
The single 400 mg dose of TAK-831 (4 × 100 mg tablets) selected for the current study is expected 
to be the highest dose level that will be assessed in upcoming studies in patients, based on PK, 
PET, and safety data from prior studies. Modeling of PET and PK data from Study TAK-831-1003 
was used to determine the relationship between brain enzyme occupancy and TAK-831 plasma 
concentration after a single dose of TAK-831 suspension. Modeling results indicated that the 
exposure to TAK-831 after a total daily dose of 400 mg (4 ×100 mg tablets) corresponded to mean 
peak target occupancy >90% and mean trough occupancy >50%. Furthermore, this dose is 
considered to be safe and tolerable as exposures are expected to fall within the range of exposures 
previously observed in the TAK-831-1001 single ascending dose study where single doses of 
TAK-831 up to 750 mg were administered.
The crossover design is appropriate for the objectives of this study because each subject receives 
both regimens (tablet-fasted and tablet-fed) and serves as his or her own control, which reduces the 
variability in the PK of TAK-831. Subjects will be randomly assigned to 1 of 2 treatment 
sequences to avoid bias. The study design is open-label, since the primary objective is to assess 
objective variables, that is, PK parameters. The current study will be performed in healthy subjects 
rather than the target patient population to collect PK, safety, and tolerability data that will not be 
confounded by any comorbidities.
An increase in exposure of TAK-831 from the T1 tablet formulation after a high-fat meal was 
observed in Study TAK-831-1001. Because of low solubility, food is also expected to increase the 


TAK-831
Study No. TAK-831-1004
Page 24 of 82
Protocol Incorporating Amendment No. 01
11 April 2017
CONFIDENTIAL
bioavailability of TAK-831 from the T2 tablet formulation. The objective of the current study is to 
estimate the magnitude of the food effect when TAK-831 (T2 tablet formulation) is 
co-administered with Ensure Plus (to be used in patients). Subjects will receive TAK-831 T2 
tablets either in the fasted state or after ingesting Ensure Plus to evaluate the effect of this 
nutritional drink on the PK of TAK-831.
In the SRD study, the mean t1/2z values of TAK-831 ranged from approximately 6 to 23 hours over 
the 10 to 750 mg dose range, with the shorter mean t1/2z values generally occurring at the lower 
doses. Therefore, a washout interval of ≥7 days between the doses is sufficient to ensure that there 
is no drug carryover effect, and collection of PK blood samples up to 72 hours postdose is 
appropriate to characterize the PK of TAK-831.
The primary PK endpoints in this study, Cmax and area under the plasma concentration-time curve 
(AUC), are standard PK parameters used to assess the effect of food on drug exposure. The use of 
standard noncompartmental PK parameters to assess the bioavailability of TAK-831 is well 
accepted in food-effect studies. Safety variables are included as the secondary endpoint (TEAEs) 
and exploratory endpoints
 to determine 
the tolerability of a single dose of TAK-831. These variables are routinely used for assessing 
safety and tolerability in clinical pharmacology studies. Additional exploratory endpoints are 
6.3
Premature Termination or Suspension of Study or Investigational Site
6.3.1
Criteria for Premature Termination or Suspension of the Study
The study will be completed as planned unless 1 or more of the following criteria are satisfied that 
require temporary suspension or early termination of the study:
!
New information or other evaluation regarding the safety or efficacy of the study drug that 
indicates a change in the known risk/benefit profile for TAK-831, such that the risk is no 
longer acceptable for subjects participating in the study.
!
Significant violation of Good Clinical Practice (GCP) that compromises the ability to achieve 
the primary study objectives or compromises subject safety.
!
Two or more subjects experience an SAE.*
!
Two or more subjects experience alanine aminotransferase (ALT) and/or aspartate 
aminotransferase (AST) elevations >5 times the upper limit of normal (ULN) in the absence of 
a concomitant bilirubin increase.*
!
One or more subjects experience ALT and/or AST elevations >3×ULN in the presence of a 
total bilirubin increase >2×ULN or an international normalized ratio (INR) >1.5 without 
findings of cholestasis or other alternate etiology to explain the elevations (ie, “Hy’s Law 
cases”).
CCI
CCI


TAK-831
Study No. TAK-831-1004
Page 25 of 82
Protocol Incorporating Amendment No. 01
11 April 2017
CONFIDENTIAL

Two or more subjects experience ALT and/or AST elevations >3×ULN with the appearance of 
fatigue, nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, and/or 
eosinophilia (>5%).*
* Please note that the study may be terminated early prior to full attainment of these criteria (eg, if 
just 1 subject experiences 1 of these events) if warranted by safety data from the other subjects 
dosed in the study to date.
6.3.2
Criteria for Premature Termination or Suspension of Investigational Sites
A study site may be terminated prematurely or suspended if the site (including the investigator) is 
found in significant violation of GCP, protocol, or contractual agreement, is unable to ensure 
adequate performance of the study, or as otherwise permitted by the contractual agreement.
6.3.3
Procedures for Premature Termination or Suspension of the Study or the 
Participation of Investigational Site
In the event that the sponsor, an institutional review board (IRB), or regulatory authority elects to 
terminate or suspend the study or the participation of a study site, a study-specific procedure for 
early termination or suspension will be provided by the sponsor; the procedure will be followed by 
applicable study sites during the course of termination or study suspension.


TAK-831
Study No. TAK-831-1004
Page 26 of 82
Protocol Incorporating Amendment No. 01
11 April 2017
CONFIDENTIAL
7.0
SELECTION AND DISCONTINUATION/WITHDRAWAL OF SUBJECTS
All entry criteria, including test results, need to be confirmed prior to randomization.
7.1
Inclusion Criteria
Subject eligibility is determined according to the following criteria prior to entry into the study:
1. In the opinion of the investigator, the subject is capable of understanding and complying with 
protocol requirements.
2. The subject signs and dates a written, informed consent form and any required privacy 
authorization prior to the initiation of any study procedures including requesting that a subject 
fast for any laboratory evaluations.
3. The subject is a healthy adult male or healthy adult female of nonchildbearing potential.
4. The subject is aged 18 to 55 years, inclusive, at the time of informed consent and first study 
drug dose.
5. The subject weighs ≥45 kg and has a body mass index (BMI) between 18.0 and 30.0 kg/m2, 
inclusive at Screening.
6. A male subject who is nonsterilized* and sexually active with a female partner of childbearing 
potential* agrees to use barrier method of contraception (eg, condom with spermicidal cream 
or jelly)* from signing of informed consent throughout the duration of the study and for 
95 days after last dose. The female partner of a male subject should also be advised to use a 
highly effective method of contraception.*
* Definitions and highly effective methods of contraception are defined in Section 9.1.9 and 
reporting responsibilities are defined in Section 9.1.10.
7.2
Exclusion Criteria
Any subject who meets any of the following criteria will not qualify for entry into the study:
1. The subject has received any investigational compound within 30 days prior to randomization.
2. The subject has received TAK-831 in a previous clinical study.
3. The subject is an immediate family member, study site employee, or is in a dependent 
relationship with a study site employee who is involved in the conduct of this study 
(eg, spouse, parent, child, sibling) or may consent under duress.
4. The subject has uncontrolled, clinically significant neurologic (including seizure disorders), 
cardiovascular, pulmonary, hepatic, renal, metabolic, gastrointestinal, urologic, immunologic, 
or endocrine disease, psychiatric disorder, or other abnormality, which may impact the ability 
of the subject to participate or potentially confound the study results. It is the responsibility of 
the investigator to assess the clinical significance; however, consultation with the Medical 
Monitor may be warranted. There is any finding in the subject’s medical history, physical 
examination, or safety laboratory tests giving reasonable suspicion of a disease that would 


TAK-831
Study No. TAK-831-1004
Page 27 of 82
Protocol Incorporating Amendment No. 01
11 April 2017
CONFIDENTIAL
contraindicate taking TAK-831, or a similar drug in the same class, or that might interfere with 
the conduct of the study.
5. The subject has evidence of current cardiovascular, CNS, hepatic, hematopoietic, renal, 
metabolic, or endocrine dysfunction, serious allergy, asthma, hypoxemia, hypertension, 
seizures, or allergic skin rash.
6. The subject has current or recent (within 6 months) gastrointestinal disease that would be 
expected to influence the absorption of drugs (ie, a history of malabsorption, esophageal 
reflux, peptic ulcer disease, erosive esophagitis, frequent [more than once per week] 
occurrence of heartburn, or any surgical intervention).
7. The subject has a lifetime history of suicidal ideation as evidenced by a score ≥3 in the 
Columbia-Suicide Severity Rating Scale (C-SSRS) at Screening or Baseline, or a history of 
suicidal behavior. 
8. The subject has a history of cancer, except basal cell carcinoma or in situ cervical cancer that 
has been in remission for ≥5 years prior to first dose of study drug.
9. The subject has a known hypersensitivity to any component of the formulation of TAK-831 or 
Ensure Plus.
10. If female, the subject is of childbearing potential (eg, premenopausal, not sterilized).
11. If male, the subject intends to donate sperm during the course of this study or for 95 days after 
the last dose of study drug.
12. The subject has a positive urine drug result for drugs of abuse (defined as any illicit drug use) at 
Screening or Check-in (Day -1) of Period 1 or 2.
13. The subject has a history of drug abuse (defined as any illicit drug use) or a history of alcohol 
abuse (defined as regular consumption of 3 or more units per day on 1 occasion per week or 
7 or more units in any given week) within 1 year prior to Screening or is unwilling to agree to 
abstain from alcohol and drugs throughout the study. One unit is equivalent to a half-pint of 
beer or 1 single measure of spirits or 1 small glass of wine. 
14. The subject has taken any excluded medications, supplements, or dietary products during the 
time periods listed in Table 7.a.
15. The subject has a positive test result for hepatitis B surface antigen (HBsAg), hepatitis C virus 
(HCV) antibody, or human immunodeficiency virus (HIV) antibody/antigen at Screening or a 
known history of HIV infection.
16. The subject has used nicotine-containing products (including but not limited to cigarettes, 
pipes, cigars, chewing tobacco, nicotine patch, or nicotine gum) within 28 days prior to 
Check-in (Day -1) of Period 1. Cotinine test is positive at Screening or Check-in (Day -1) of 
Period 1 or 2. 
17. The subject has poor peripheral venous access.


TAK-831
Study No. TAK-831-1004
Page 28 of 82
Protocol Incorporating Amendment No. 01
11 April 2017
CONFIDENTIAL
18. The subject has donated or lost 450 mL or more of his or her blood volume (including 
plasmapheresis), or had a transfusion of any blood product within 45 days prior to first dose of 
study drug.
19. The subject has an abnormal (clinically significant) ECG at Screening or Check-in (Day -1) of 
Period 1 or 2. Entry of any subject with an abnormal (not clinically significant) ECG must be 
approved and documented by signature by the principal investigator or designee.
20. The subject has a QT interval with Fridericia correction method (QTcF) >450 msec (males) or 
>470 msec (females) or PR interval outside the range of 120 to 220 msec, confirmed with 
1 repeat testing, at Screening or Check-in (Day -1) of Period 1 or 2.
21. The subject has a supine blood pressure outside of the range of 90 to 140 mm Hg for systolic 
and 50 to 90 mm Hg for diastolic, confirmed on repeat testing within a maximum of 
30 minutes, at Screening or Check-in (Day -1) of Period 1 or 2.
22. The subject has a resting heart rate outside of the range of 40 to 100 beats per minute, 
confirmed on repeat testing within a maximum of 30 minutes, at Screening Visit or Check-in 
(Day -1) of Period 1 or 2.
23. The subject has abnormal clinical laboratory test values that suggest a clinically significant 
underlying disease or has ALT and/or AST >1.5×ULN at Screening or Check-in (Day -1) of 
Period 1 or 2.
24. The subject has any dietary restrictions or preferences that may interfere with the conduct of 
the study.
7.3
Excluded Medications, Supplements, Dietary Products
Use of the agents listed in Table 7.a is prohibited from the time points specified until completion of 
all study-related activities, including the Follow-up Phone Call.


TAK-831
Study No. TAK-831-1004
Page 29 of 82
Protocol Incorporating Amendment No. 01
11 April 2017
CONFIDENTIAL
Table 7.a
Excluded Medications, Supplements, and Dietary Products
28 Days Prior to Check-in 
(Day -1) of Period 1
7 Days Prior to Check-in 
(Day -1) of Period 1
72 Hours Prior to Check-in 
(Day -1) of Period 1
Prescription medications (including 
hormone replacement therapy)
OTC medications (a)
Caffeine- or xanthine-containing 
products
Nutraceuticals (eg, St. John’s wort, 
ginseng, kava kava, ginkgo biloba, 
Chinese herbs, and melatonin)
Vitamin supplements
Poppy seeds
Immunization/vaccines (b) 
Foods or beverages containing 
grapefruit or grapefruit juice, star 
fruit or star fruit juice, Seville-type 
(sour) oranges or marmalade, apple 
juice, orange juice, pineapple juice, 
vegetables from the mustard green 
family (eg, kale, broccoli, watercress, 
collard greens, kohlrabi, Brussels 
sprouts, mustard), and charbroiled 
meats
Nicotine-containing products
Alcohol-containing products
Intake of known OTC 
inhibitors/inducers of CYPs 3A4/5, 
2C9, 2C19, 2D6, 1A2, 2B6, 2E1, and 
2A6 (c)
CYP=cytochrome P-450, OTC=over-the-counter.
(a) Occasional use of acetaminophen (1 g/day) or other medication as approved by Takeda on a case-by-case basis is 
allowed.
(b) Inclusive of but not limited to H1N1 and other influenza vaccinations.
(c) Omeprazole, lansoprazole, cimetidine, ranitidine, and chlorpheniramine.
Subjects must be instructed not to take any medications, including OTC products, without first 
consulting with the investigator.
7.4
Diet, Fluid, Activity Control
Subjects will be confined to the clinic from Check-in (Day -1) through completion of study 
procedures on Day 3 in each period. 
During each confinement period, subjects will be served standardized meals (except for Ensure 
Plus) and an evening snack, each containing ~30% fat (relative to total calories), and no additional 
food or drink (except for Ensure Plus for Regimen B and water for both regimens) will be allowed. 
For each regimen, the meals served on the day of dosing (Day 1) should be identical for all 
subjects. The study menu should be recorded and submitted to the study file with a copy provided 
to the sponsor before the start of the study. The meal start and stop times and the amount consumed 
will be recorded in the source document and appropriate electronic case report form (eCRF) page 
for the Day -1 snack and all meals (including Ensure Plus) served on Day 1.
For each regimen, TAK-831 will be administered on Day 1 after an overnight fast of ≥10 hours. 
For Regimen A (fasted state), subjects will be orally administered TAK-831 with 240 mL of water. 


TAK-831
Study No. TAK-831-1004
Page 30 of 82
Protocol Incorporating Amendment No. 01
11 April 2017
CONFIDENTIAL
For Regimen B (fed state), subjects will start consuming Ensure Plus 15 minutes before oral 
administration of TAK-831. Ensure Plus is a nutritional drink of 237 mL (8 fl oz) and has 355 total 
calories. Of the total calories, 103 calories are from fat, with the total fat content (11 g) being 17% 
of the daily value based on a 2000 calorie diet; 52 calories are from protein, with the total protein 
content (13 g) being 26% of the daily value based on a 2000 calorie diet; and 201 calories are from 
carbohydrate, with the total carbohydrate content (51 g) being 17% of the daily value based on a 
2000 calorie diet. Subjects should complete the Ensure Plus in 15 minutes or less; TAK-831 
should be administered with 240 mL of water 15 minutes after the start of this meal. For each 
regimen, subjects will fast for an additional 4 hours after dosing. Subjects will be allowed to 
consume water ad libitum except for 1 hour before dosing and 1 hour after dosing. 
For each regimen, subjects will not receive breakfast on Day 1 (dosing day). Lunch will be served 
4 hours after dosing (after the 4-hour PK and PD blood sample collections), dinner ~9 hours after 
dosing, and a snack ~12 hours after dosing (after the 12-hour PK and PD blood sample 
collections). No meals will be served after the snack. Subjects will be fasting for ≥10 hours before 
collection of blood samples for clinical laboratory tests (except for those collected at Screening).
If a blood draw or any other study procedure coincides with a meal, the blood draw will take 
precedence, followed by the study procedure, and then the meal.
Foods and beverages that are prohibited during the study are listed in Table 7.a.
Subjects will remain upright (seated, standing, or ambulatory) for 4 hours after dosing, except as 
necessitated by the occurrence of an adverse event (AE) or study procedures (eg, obtaining 12-lead 
ECG). Subjects will refrain from strenuous and/or unaccustomed exercise throughout the entire 
study until Study Exit.
7.5
Criteria for Discontinuation or Withdrawal of a Subject
The primary reason for discontinuation or withdrawal of the subject from the study or study drug 
should be recorded in the eCRF using the following categories. For screen failure subjects, refer to 
Section 9.1.17.
1. Pretreatment event (PTE) or AE. The subject has experienced a PTE or AE that requires early 
termination because continued participation imposes an unacceptable risk to the subject’s 
health or the subject is unwilling to continue because of the PTE or AE.

Liver Function Test (LFT) Abnormalities
Study drug should be discontinued immediately with appropriate clinical follow-up 
(including repeat laboratory tests, until a subject’s laboratory profile has returned to 
normal/baseline status, see Section 9.1.8), if the following circumstances occur at any time 
during study drug treatment:
–
ALT or AST >8×ULN, or
–
ALT or AST >5×ULN and persists for >2 weeks or based on clinical judgment of the 
investigator, or


TAK-831
Study No. TAK-831-1004
Page 31 of 82
Protocol Incorporating Amendment No. 01
11 April 2017
CONFIDENTIAL
–
ALT or AST >3×ULN in conjunction with elevated total bilirubin >2×ULN or 
INR >1.5, or
–
ALT or AST >3×ULN with appearance of fatigue, nausea, vomiting, right upper 
quadrant pain or tenderness, fever, rash, and/or eosinophilia (>5%).
2. Significant protocol deviation. The discovery postrandomization that the subject failed to meet 
protocol entry criteria or did not adhere to protocol requirements, and continued participation 
poses an unacceptable risk to the subject’s health.
3. Lost to follow-up. The subject did not return to the clinic and attempts to contact the subject 
were unsuccessful. Attempts to contact the subject must be documented in the subject’s source 
documentation.
4. Voluntary withdrawal. The subject (or subject’s legally acceptable representative) wishes to 
withdraw from the study. The reason for withdrawal, if provided, should be recorded in the 
eCRF.
Note: All attempts should be made to determine the underlying reason for the withdrawal and, 
where possible, the primary underlying reason should be recorded (ie, withdrawal because of 
an AE should not be recorded in the “voluntary withdrawal” category).
5. Study termination. The sponsor, IRB, or regulatory agency terminates the study.
6. Pregnancy. The subject is found to be pregnant.
Note: If the subject is found to be pregnant, the subject must be withdrawn immediately. The 
procedure is described in Section 9.1.10.
7. Severe gastrointestinal intolerance. The subject develops severe gastrointestinal intolerance 
that cannot be ameliorated by supportive treatment.
8. Other.
Note: The specific reasons should be recorded in the “specify” field of the eCRF.
7.6
Procedures for Discontinuation or Withdrawal of a Subject
The investigator may discontinue a subject’s study participation at any time during the study when 
the subject meets the discontinuation criteria described in Section 7.5. In addition, a subject may 
discontinue his or her participation without giving a reason at any time during the study. Should a 
subject’s participation be discontinued, the primary criterion for termination must be recorded by 
the investigator. In addition, efforts should be made to perform all procedures scheduled for the 
Early Termination Visit. Discontinued or withdrawn subjects may be considered for replacement 
on a case by case basis.


TAK-831
Study No. TAK-831-1004
Page 32 of 82
Protocol Incorporating Amendment No. 01
11 April 2017
CONFIDENTIAL
8.0
CLINICAL STUDY MATERIAL MANAGEMENT
This section contains information regarding all medications and materials provided directly by the 
sponsor, and/or sourced by other means, that are required by the study protocol, including 
important sections describing the management of study material.
8.1
Study Drug and Materials
8.1.1
Dosage Form, Manufacturing, Packaging, and Labeling
In this protocol, the term “study drug” refers to all or any of the drugs defined below.
8.1.1.1
Study Drug
TAK-831 T2 100 mg tablets will be provided as unmarked, yellow-red, film-coated tablets for oral 
administration. TAK-831 is manufactured by Takeda Pharmaceuticals, Osaka, Japan. The 
TAK-831 T2 100 mg tablets will be supplied in amber glass bottles with metal screw caps, with 
each bottle containing 32 tablets. Each bottle will be labeled with an open-label, single-panel label. 
The label will include pertinent study information and appropriate country-specific regulatory 
caution statements.
8.1.1.2
Ancillary Materials
Ensure Plus will be provided by the site. This nutritional drink has a total volume of 237 mL 
(8 fl oz) and 355 total calories. Of the total calories, 103 calories are from fat (total fat content is 
17% of daily value), 201 calories are from carbohydrate (total carbohydrate content is 17% of 
daily value), and 52 calories are from protein (total protein content is 26% of daily value).
8.1.1.3
Sponsor-Supplied Drug 
Sponsor-supplied drugs referenced in other sections of the protocol include the following: 
TAK-831 T2 100 mg tablets.
8.1.2
Storage
Study drug (TAK-831 T2 100 mg tablets) and ancillary materials (Ensure Plus) must be kept in an 
appropriate, limited-access, secure place until used or returned to the sponsor or designee for 
destruction. Study drug must be stored under the conditions specified on the label and remain in 
the original container until dispensed. A daily temperature log of the drug storage area must be 
maintained every working day.
8.1.3
Dose and Regimen
The study drug supplies for each treatment period are indicated in Table 8.a.


TAK-831
Study No. TAK-831-1004
Page 33 of 82
Protocol Incorporating Amendment No. 01
11 April 2017
CONFIDENTIAL
Table 8.a
Study Drug Supplies per Treatment Period
Treatment Sequence
Regimen
Period 1
Period 2
1
A
B
2
B
A
Regimen A=a single oral dose of 4 TAK-831 100 mg tablets (T2 formulation; total dose 400 mg) administered on Day 1 with water; 
Regimen B=a single oral dose of 4 TAK-831 100 mg tablets (T2 formulation; total dose 400 mg) administered on Day 1, 
15 minutes after starting ingestion of Ensure Plus. For both regimens, subjects will fast for ≥10 hours overnight before dosing.
8.1.4
Overdose
An overdose is defined as a known deliberate or accidental administration of study drug, to or by a 
study subject, at a dose above that which is assigned to that individual subject according to the 
study protocol.
All cases of overdose (with or without associated AEs) will be documented on an Overdose page 
of the eCRF, in order to capture this important safety information consistently in the database. 
Cases of overdose without manifested signs or symptoms are not considered AEs. AEs associated 
with an overdose will be documented on the AE page of the eCRF, according to Section 10.0.
SAEs associated with overdose should be reported according to the procedure outlined in 
Section 10.2.2.
In the event of drug overdose, the subject should be treated symptomatically.
8.2
Study Drug Assignment and Dispensing Procedures
Subjects will be assigned, in the order in which they are randomized into the study, to receive their 
treatment according to the randomization schedule allocated to the site.
Subjects will be assigned to receive a 4-digit randomization number. The number will be assigned 
by the study site personnel in sequential order beginning with 1001 and ending with 1016. This 
4-digit number will be used by the study site to facilitate the prelabeling of PK and PD samples, 
and will be the only subject identifier used on all PK and PD sample collections. It should also be 
contained on the PK transport vials shipped to the bioanalytical laboratory, and will be used by the 
laboratory to report the subject results. This 4-digit number should only be used for the purposes 
described in this section. It does not replace the subject identification number, which is assigned at 
the time the informed consent is obtained and is used for all other procedures to identify the 
subjects throughout the study.
8.3
Randomization Code Creation and Storage
Randomization personnel of the sponsor or its designee will generate the randomization schedule 
and will provide it to the site pharmacist prior to the start of this study. All randomization 
information will be stored in a secured area, accessible only by authorized personnel.


TAK-831
Study No. TAK-831-1004
Page 34 of 82
Protocol Incorporating Amendment No. 01
11 April 2017
CONFIDENTIAL
8.4
Accountability and Destruction of Sponsor-Supplied Drugs
Drug supplies will be counted and reconciled at the site before being returned to the sponsor or 
designee.
The investigator or designee must ensure that the sponsor-supplied drug is used in accordance with 
the protocol and is dispensed only to subjects enrolled in the study. To document appropriate use 
of sponsor-supplied drug (TAK-831 T2 100 mg tablets), the investigator or designee must 
maintain records of all sponsor-supplied drug delivery to the site, site inventory, dispensation and 
use by each subject, and return to the sponsor or designee.
Upon receipt of sponsor-supplied drug, the investigator or designee must verify the contents of the 
shipments against the packing list. The verifier should ensure that the quantity is correct, and the 
study drug is in good condition. If quantity and conditions are acceptable, investigator or designee 
should acknowledge the receipt of the shipment by emailing per instructions on the form. If there 
are any discrepancies between the packing list versus the actual product received, Takeda must be 
contacted to resolve the issue. The packing list should be filed in the investigator’s essential 
document file.
The investigator or designee must maintain 100% accountability for all sponsor-supplied drugs 
received and dispensed during his or her entire participation in the study. Proper drug 
accountability includes, but is not limited to the following:

Continuously monitoring expiration dates if expiry date is provided to the investigator or 
designee. 

Frequently verifying that actual inventory matches documented inventory.

Verifying that the log is completed for the lot used to prepare each dose.

Verifying that all containers used are documented accurately on the log.

Verifying that required fields are completed accurately and legibly.

A site representative or unblinded pharmacy monitor, otherwise uninvolved with study 
conduct, will review the randomization schedule and subject dosing log prior to Day 1 in 
Periods 1 and 2.
If any dispensing errors or discrepancies are discovered, the sponsor must be notified immediately.
The investigator or designee must record the current inventory of all sponsor-supplied drugs 
(TAK-831 T2 100 mg tablets) on a sponsor-approved drug accountability log. The following 
information will be recorded at a minimum: protocol number and title, name of investigator, site 
identifier and number, description of sponsor-supplied drugs expiry date, date and amount 
dispensed, including initials, seal, or signature of the person dispensing the drug, and the date and 
amount returned to the site by the subject, including the initials, seal, or signature of the person 
receiving the sponsor-supplied drug. The log should include all required information as a separate 
entry for each subject to whom sponsor-supplied drug is dispensed.


TAK-831
Study No. TAK-831-1004
Page 35 of 82
Protocol Incorporating Amendment No. 01
11 April 2017
CONFIDENTIAL
All study drug not returned to the site by a subject must be investigated by the site and 
appropriately documented on the drug accountability log.
Prior to site closure or at appropriate intervals, a representative from the sponsor or its designee 
will perform sponsor-supplied drug accountability and reconciliation before sponsor-supplied 
drugs are returned to the sponsor or its designee for destruction. The investigator or designee will 
retain a copy of the documentation regarding sponsor-supplied drug accountability, return, and/or 
destruction, and originals will be sent to the sponsor or designee.
The investigator will be notified of any expiry date or retest date extension of sponsor-supplied 
drug during the study conduct. On expiry date notification from the sponsor or designee, the site 
must complete all instructions outlined in the notification, including segregation of expired 
sponsor-supplied drug for return to the sponsor or its designee for destruction.


TAK-831
Study No. TAK-831-1004
Page 36 of 82
Protocol Incorporating Amendment No. 01
11 April 2017
CONFIDENTIAL
9.0
STUDY PLAN
9.1
Study Procedures
The following sections describe the study procedures to be performed and data to be collected. For 
each procedure, subjects are to be assessed by the same investigator or site personnel whenever 
possible. The Schedule of Study Procedures is located in Appendix A.
9.1.1
Informed Consent Procedure
The requirements of the informed consent are described in Section 15.2.
Informed consent must be obtained prior to the subject entering into the study, and before any 
protocol-directed procedures are performed, including requesting that a subject fast for laboratory 
evaluations.
A unique subject identification number (subject number) will be assigned to each subject at the 
time that informed consent is obtained; this subject number will be used throughout the study.
9.1.1.1
Pharmacogenomics Informed Consent Procedure
Pharmacogenomics (PGx) informed consent is a component of the overall study informed consent. 
The requirements are described in Section 15.2. PGx sample collection is mandatory.
9.1.2
Demographics, Medical History, and Medication History Procedure
Demographics to be obtained will include date of birth, sex, Hispanic ethnicity, race as described 
by the subject, height, weight, caffeine consumption, xanthine consumption, alcohol use, 
reproductive status, and smoking status of the subject at Screening.
Medical history to be obtained will include determining whether the subject has any significant 
conditions or diseases relevant to the disease under study that resolved at or prior to signing of 
informed consent. Ongoing conditions are considered concurrent medical conditions (see 
Section 9.1.7).
Medication history information to be obtained includes any medication relevant to eligibility 
criteria stopped at or within 28 days prior to signing of informed consent.
9.1.3
Physical Examination Procedure
A baseline physical examination (defined as the assessment prior to the first dose of study drug)
will consist of the following body systems: (1) eyes; (2) ears, nose, throat; (3) cardiovascular 
system; (4) respiratory system; (5) gastrointestinal system; (6) dermatologic system; 
(7) extremities; (8) musculoskeletal system; (9) nervous system; (10) lymph nodes; and (11) other.
Any abnormal finding on a pretreatment physical examination assessment must be assessed as not 
clinically significant or clinically significant by the investigator and recorded in the source 
document and eCRF. All clinically significant findings/changes will be recorded as a PTE or 
concurrent medical condition in the source document and in the eCRF.


TAK-831
Study No. TAK-831-1004
Page 37 of 82
Protocol Incorporating Amendment No. 01
11 April 2017
CONFIDENTIAL
On subsequent examinations, any abnormal change from the baseline physical examination must 
be assessed as not clinically significant or clinically significant by the investigator and recorded in 
the source document and eCRF. Any clinically significant change or new diagnosis as a result of a 
clinically significant change, as determined by the investigator, will be recorded as an AE in the 
source document and on the PTE/AE page of the eCRF.
9.1.4
Weight, Height and BMI
A subject should have weight and height measured while wearing indoor clothing and with shoes 
off. The BMI is calculated using metric units with the formula provided below. Height is recorded 
in centimeters without decimal places and weight is recorded in kilograms (kg) with 1 decimal 
place. BMI should be derived as follows:
Metric:
 =
	
 ()
	
 ()
Note that although height is reported in centimeters, the formula uses meters for height; meters can 
be determined from centimeters by dividing by 100. Thus, for example, if height=176 cm 
(1.76 meters) and weight=79.2 kg, then BMI=79.2/1.762=25.56818 kg/m2.
The values should be reported to 1 decimal place by rounding. Thus, in the above example BMI 
would be reported as 25.6 kg/m2. Since BMI is used as an entry criterion, this determination must 
be made after rounding.
9.1.5
Vital Sign Procedure
Vital signs will include oral body temperature, respiratory rate, blood pressure, and heart rate 
(beats per minute). Blood pressure and heart rate will be measured in 2 positions: after 5 minutes 
supine and then after 1 and 3 minutes standing.
Vital signs should be measured at the same time of the day across visits, if possible. When vital 
signs are scheduled at the same time as blood draws, the blood draw will take priority and vital 
signs will be obtained within 0.5 hours before or after the scheduled blood draw.
9.1.6
Documentation of Concomitant Medications
Concomitant medication is any drug given in addition to the study drug. These may be prescribed 
by a physician or obtained by the subject over the counter. Concomitant medication is not provided 
by Takeda. At each study visit, subjects will be asked whether they have taken any medication 
other than the study drug (used from signing of informed consent through the end of the study), 
and all medication including vitamin supplements, OTC medications, and oral herbal preparations, 
must be recorded in the eCRF. Documentation will include generic medication name, dose, unit, 
frequency, route of administration, start and end dates, and reason for use.
9.1.7
Documentation of Concurrent Medical Conditions
Concurrent medical conditions are those significant ongoing conditions or diseases that are present 
at signing of informed consent. This includes clinically significant laboratory, ECG, or physical 


TAK-831
Study No. TAK-831-1004
Page 38 of 82
Protocol Incorporating Amendment No. 01
11 April 2017
CONFIDENTIAL
examination abnormalities noted at the screening or baseline examination. The condition (ie, 
diagnosis) should be described.
9.1.8
Procedures for Clinical Laboratory Samples
All samples will be collected in accordance with acceptable laboratory procedures. Laboratory 
samples will be collected following an overnight fast of ≥10 hours (except for those collected at 
Screening) on the days stipulated in the Schedule of Study Procedures in Appendix A. 
The tests that will be performed for each clinical laboratory specimen are listed in Table 9.a.
Table 9.a
Clinical Laboratory Tests
Hematology
Serum Chemistry
Urinalysis
RBCs
WBCs with differential (% and 
absolute)
Hemoglobin
Hematocrit
Platelets
Prothrombin time/INR
aPTT
ALT
Albumin
Alkaline phosphatase
AST
Total bilirubin
Direct bilirubin
Total protein
Creatinine
Blood urea nitrogen
Creatine kinase
GGT
Potassium
Sodium
Glucose
Chloride
Bicarbonate
Calcium
pH
Specific gravity
Protein
Glucose
Blood
Nitrite
Microscopic Analysis: (a)
RBC/high power field
WBC/high power field
Epithelial cells, casts, etc
Diagnostic Screening:
Serum
Urine
HIV (b)
Drug screen including amphetamines, 
barbiturates, benzodiazepines, cannabinoids, 
cocaine, opiates, alcohol, and cotinine (c)
HBsAg and anti-HCV (b)
Female subjects only:
hCG (for pregnancy) (d)
FSH (b) (e)
aPTT=activated partial thromboplastin time, FSH=follicle-stimulating hormone, GGT=-glutamyl transferase, hCG=human 
chorionic gonadotropin, RBC=red blood cell, WBC=white blood cell.
(a) Microscopic examination of sediment to be performed only if the dipstick results are positive.
(b) To be performed at Screening only.
(c) To be performed at Screening and Check-in (Day -1) of Periods 1 and 2.
(d) To be performed at Screening, Check-in (Day -1) of Period 1, and Study Exit/Early Termination.
(e) For female subjects when menopause is suspected and subject is not surgically sterile.
The local laboratory will perform laboratory tests for hematology, serum chemistry, and 
urinalysis. The results of laboratory tests will be returned to the investigator, who is responsible for 
reviewing and filing these results.


TAK-831
Study No. TAK-831-1004
Page 39 of 82
Protocol Incorporating Amendment No. 01
11 April 2017
CONFIDENTIAL
If subjects experience ALT or AST >3×ULN, follow-up laboratory tests (at a minimum, serum 
alkaline phosphatase, ALT, AST, total bilirubin, GGT, and INR) should be performed preferably 
within 48 to 72 hours and no later than 7 days after the abnormality was noted (please refer to 
Section 7.5 for discontinuation criteria and Section 10.2.3 for reporting requirements related to 
abnormal LFT results).
If the ALT or AST remains elevated >3×ULN on these 2 consecutive occasions, the investigator 
must contact the Medical Monitor for consideration of additional testing, close monitoring, 
possible discontinuation of study drug, discussion of the relevant subject details and possible 
alternative etiologies. The abnormality should be recorded as an AE (please refer to Section 10.2.3
for reporting requirements related to abnormal LFT results).
The investigator or designee is responsible for transcribing or attaching laboratory results to the 
eCRF. The investigator will maintain a copy of the laboratory accreditation and the reference 
ranges for the laboratory used.
Laboratory reports must be signed and dated by the principal investigator indicating that the report 
has been reviewed and any abnormalities have been assessed for clinical significance. Any 
abnormalities identified prior to the first dose of study drug will require clear and complete 
documentation in the source documents as to the investigator’s assessment of not clinically 
significant before proceeding with enrollment or randomization.
All clinically significant laboratory abnormalities must be recorded as a PTE/AE in the subject’s 
source documents and on the appropriate eCRF. A clinically significant laboratory abnormality 
that has been verified by retesting will be followed until the abnormality returns to an acceptable 
level or a satisfactory explanation has been obtained.
9.1.9
Contraception and Pregnancy Avoidance Procedure
9.1.9.1
Male Subjects and Their Female Partners
From signing of informed consent, throughout the duration of the study, and for 95 days after the 
last dose of study drug, nonsterilized** male subjects who are sexually active with a female 
partner of childbearing potential* must use barrier contraception (eg, condom with spermicidal 
cream or jelly). In addition, they must be advised not to donate sperm during this period. Women 
of childbearing potential who are partners of male subjects are also advised to use additional 
contraception as shown in the list containing highly effective contraception below. If the female 
partner has been using 1 of the hormonal contraceptives methods listed below for >3 months, 
condom use is advised but not mandated.
9.1.9.2
Female Subjects and Their Male Partners
Women of childbearing potential will not be included in this study.


TAK-831
Study No. TAK-831-1004
Page 40 of 82
Protocol Incorporating Amendment No. 01
11 April 2017
CONFIDENTIAL
9.1.9.3
Definitions and Procedures for Contraception and Pregnancy Avoidance
The following definitions apply for contraception and pregnancy avoidance procedures.
* A woman is considered a woman of childbearing potential, that is, fertile, following menarche 
and until becoming postmenopausal unless permanently sterile. Permanent sterilization methods 
include hysterectomy, bilateral tubal ligation, and bilateral oophorectomy. A postmenopausal state 
is defined as no menses for 12 months without an alternative medical cause. A high FSH level in 
the postmenopausal range (FSH >40 IU/L) may be used to confirm a postmenopausal state in 
younger women (eg, those <45 years old) or women who are not using hormonal contraception or 
hormonal replacement therapy. However, in the absence of 12 months of amenorrhea, a single 
FSH measurement is insufficient.
** Sterilized males should be ≥1 year post–bilateral vasectomy and have confirmed that they have 
obtained documentation of the absence of sperm in the ejaculate or have had bilateral 
orchidectomy.
The following procedures apply for contraception and pregnancy avoidance.
1. Highly effective methods of contraception are defined as those, alone or in combination, that 
result in a low failure rate (ie, <1% failure rate per year when used consistently and correctly). 
In this study, where medications and devices containing hormones are permitted, the only 
acceptable methods of contraception are as follows: 

Nonhormonal Methods: 

Intrauterine device. 

Bilateral tubal occlusion. 

Vasectomized partner (provided that the vasectomized partner has received medical 
assessment of the surgical success). 

True sexual abstinence, only if this is in line with the preferred and usual lifestyle of the 
subject. True abstinence is defined as refraining from heterosexual intercourse during 
the entire period of the study, from 1 month before the first dose of study drug until 
95 days after last dose.

Hormonal Methods:

Combined (estrogen and progestogen) hormonal contraception associated with 
inhibition of ovulation initiated ≥3 months before the first dose of study drug OR 
combined with a barrier method (male condom, female condom, or diaphragm) if for 
shorter duration until the female partner has been on contraceptive for 3 months:

Oral.

Intravaginal (eg, ring).

Transdermal.


TAK-831
Study No. TAK-831-1004
Page 41 of 82
Protocol Incorporating Amendment No. 01
11 April 2017
CONFIDENTIAL

Progestogen-only hormonal contraception associated with inhibition of ovulation 
initiated ≥3 months before the first dose of study drug OR combined with a barrier 
method (male condom, female condom, or diaphragm) if shorter until the female 
partner has been on contraceptive for 3 months:

Oral.

Injectable.

Implantable.
2. Unacceptable methods of contraception are as follows:

Periodic abstinence (eg, calendar, ovulation, symptothermal, postovulation methods).

Spermicides only.

Withdrawal.

No method at all.

Use of female and male condoms together.

Cap/diaphragm/sponge without spermicide and without condom.
3. Subjects will be provided with information on highly effective methods of contraception as 
part of the subject informed consent process and will be asked to sign a consent form stating 
that they understand the requirements for avoidance of pregnancy and sperm donation during 
the course of the study.
4. During the course of the study, regular serum hCG pregnancy tests will be performed only for 
female subjects and all subjects (male and female) will receive continued guidance with 
respect to the avoidance of pregnancy and sperm donation as part of the study procedures. 
Such guidance should include a reminder of the following:

Contraceptive requirements of the study.

Reasons for use of barrier methods (ie, condom) in males with pregnant partners.

Assessment of subject compliance through questions such as the following:

Have you used the contraception consistently and correctly since the last visit?

Have you forgotten to use contraception since the last visit?

Is there a chance that your partner could be pregnant?
5. In addition to a negative serum hCG pregnancy test at Screening, female subjects must also 
have a negative serum hCG pregnancy test on Day -1 of Period 1 before receiving the first dose 
of study drug.


TAK-831
Study No. TAK-831-1004
Page 42 of 82
Protocol Incorporating Amendment No. 01
11 April 2017
CONFIDENTIAL
9.1.10 Pregnancy
Women of childbearing potential will not be included in this study.
If any subject is found to be pregnant during the study she should be withdrawn and any 
sponsor-supplied drug (TAK-831) should be immediately discontinued. In addition, any 
pregnancies in the female partner of a male subject during the study or for 95 days after the last 
dose of study drug should also be recorded following authorization from the subject’s partner.
If the pregnancy occurs during administration of active study drug, for example, after Day 1 of 
Period 1 or within 95 days of the last dose of active study drug, the pregnancy should be reported 
immediately, using a pregnancy notification form, to the contact listed in Section 1.0.
If the female subject or female partner of a male subject agrees to the primary care physician being 
informed, the investigator should notify the primary care physician that the female subject/female 
partner of the subject was participating in a clinical study at the time she became pregnant and 
provide details of treatment the subject received.
All reported pregnancies, including those in female partners of male subjects, will be followed up 
to final outcome, using the pregnancy form. The outcome, including any premature termination, 
must be reported to the sponsor. An evaluation after the birth of the child will also be conducted.
9.1.11 ECG Procedure
Standard 12-lead ECGs will be recorded. When an ECG is scheduled at the same time as the blood 
draws or vital signs, then the blood draws and vital signs will take priority and the ECG will be 
obtained within 0.5 hours before or after the scheduled blood draw or vital sign assignment. If an 
ECG coincides with a meal, the ECG will take precedence followed by the meal.
All 12-lead ECG machines will be supplied by the study site. Subjects should be in a supine 
position following an approximate 5-minute rest period for ECG recordings. Should technical 
difficulties occur during recording of the ECG, a reasonable attempt should be made to repeat the 
ECG shortly after the failed attempt.
The investigator (or a qualified observer at the study site) will manually interpret the ECG using 1 
of the following categories: within normal limits, abnormal but not clinically significant, or 
abnormal and clinically significant. The time that the ECG was performed will be recorded. The 
following parameters will be calculated automatically by the ECG machine and recorded on the 
eCRF: heart rate, RR interval, PR interval, QT interval, QRS interval, QT interval with Bazett 
correction method (QTcB), and QTcF interval. QTcF interval may be calculated manually by the 
study site. The QTcF interval is calculated as shown below:
 = 
√

One copy of the 12-lead ECG with the physician’s signature and date of assessment will be filed 
with the source documents and captured in the appropriate eCRF. If the original ECG is printed on 


TAK-831
Study No. TAK-831-1004
Page 43 of 82
Protocol Incorporating Amendment No. 01
11 April 2017
CONFIDENTIAL
thermal paper, the ECG report must be photocopied and certified. The photocopy will be filed with 
the original ECG in the source. The study site uses a fully validated ECG system. The investigator 
assessment is recorded electronically within this system.
9.1.12 PGx Sample Collection
DNA forms the basis for the genes that make the body produce proteins such as enzymes, drug 
transporters, or drug targets, and may be evaluated for the genetic contribution to how the drug is 
broken down or how the drug affects the body. This is called a “PGx research study.” Specific 
purposes of this study include the following:

Identifying genetic reasons why certain people respond differently to TAK-831.

Finding out more information about how TAK-831 works.

Generating information needed for research, development, and regulatory approval of tests to 
predict response to TAK-831.

Identifying variations in genes related to the biological target of TAK-831.
This information may be used, for example, to develop a better understanding of the safety and 
efficacy of TAK-831 and other study drugs, and to improve the efficiency, design, and study 
methods of future research studies.
One 6-mL whole blood sample for DNA isolation will be collected at time point indicated in the 
Schedule of Study Procedures (Appendix A).
A portion of the DNA samples will be used to evaluate drug metabolic enzyme and transporter 
polymorphisms that may contribute to the variability in the PK of TAK-831. Also, since PGx is an 
evolving science, many genes and their functions are not yet fully understood. Future data may 
suggest a role of some of these genes in drug response, which may lead to additional 
hypothesis-generating exploratory research and diagnostic development on stored samples.
Detailed instructions for collecting, storing, handling, and shipping the PGx blood samples are 
provided in the laboratory manual.
9.1.13 PK Sample Collection
9.1.13.1 Collection of Blood for PK Sampling
Serial blood samples (one 4-mL sample per scheduled time) for PK analysis of TAK-831 will be 
collected into chilled Vacutainers containing the anticoagulant K2EDTA, according to the 
schedule shown in Table 9.b.


TAK-831
Study No. TAK-831-1004
Page 44 of 82
Protocol Incorporating Amendment No. 01
11 April 2017
CONFIDENTIAL
Table 9.b
Collection of Blood Samples for PK Analysis
Analyte
Analysis 
Matrix
Dosing Day
(Periods 1 and 2)
Time 
TAK-831
Plasma
1
Predose (0 hour, within 15 minutes prior to dose) and 0.25, 
0.5, 1, 1.5, 2, 3, 4, 8, 12, 24, 36, 48, and 72 hours postdose.
The actual time of sample collection will be recorded on the source document and eCRF.
Instructions for sample processing and shipment are provided in the laboratory manual.
9.1.13.2 Bioanalytical Methods
Plasma concentrations of TAK-831 will be measured by high-performance liquid chromatography 
with tandem mass spectrometry.
9.1.14 PK Parameters
The plasma PK parameters of TAK-831 will be determined from the plasma concentration-time 
profiles for all evaluable subjects using noncompartmental analysis. Actual sampling times, rather 
than scheduled sampling times, will be used in all computations involving sampling times. The 
plasma PK parameters that will be calculated from TAK-831 plasma concentrations for each 
regimen are shown in Table 9.c.
Table 9.c
Plasma PK Parameters
Symbol/Term
Definition
AUClast
Area under the plasma concentration-time curve from time 0 to time of the last quantifiable 
concentration.
AUC∞
Area under the plasma concentration-time curve from time 0 to infinity, calculated using the 
observed value of the last quantifiable concentration.
Cmax
Maximum observed plasma concentration.
CL/F
Apparent clearance after extravascular administration, calculated using the observed value of 
the last quantifiable concentration.
λz
Terminal disposition phase rate constant.
t1/2z
Terminal disposition phase half-life. 
tmax
Time of first occurrence of Cmax.
Vz/F
Apparent volume of distribution during the terminal disposition phase after extravascular 
administration, calculated using the observed value of the last quantifiable concentration.
Additional PK parameters may be calculated as appropriate.
9.1.15 PD Sample Collection
Serial blood samples (one 6-mL sample per scheduled time) for PD analysis of TAK-831 will be 
collected into chilled Vacutainers containing the anticoagulant K2EDTA, according to the 
schedule shown in Table 9.d.


TAK-831
Study No. TAK-831-1004
Page 45 of 82
Protocol Incorporating Amendment No. 01
11 April 2017
CONFIDENTIAL
Table 9.d
Collection of Blood Samples for PD Analysis
The actual time of sample collection will be recorded on the source document and eCRF.
Instructions for sample processing and shipment are provided in the laboratory manual.
9.1.16 PD Parameters
PD parameters will be determined from the concentration-time profiles for all evaluable subjects. 
Actual sampling times, rather than scheduled sampling times, will be used in all computations 
involving sampling times. 
 
9.1.17 Documentation of Screen Failure
Investigators must account for all subjects who sign informed consent. If the subject is withdrawn 
at the Screening Visit, the investigator should complete the screen failure page of the eCRF.
The primary reason for screen failure is recorded in the eCRF using the following categories:
!
PTE/AE.
!
Did not meet inclusion criteria or did meet exclusion criteria.
!
Significant protocol deviation.
!
Lost to follow-up.
!
Voluntary withdrawal (specify reason).
!
Study termination.
!
Other (specify reason).
Subject numbers assigned to subjects who fail Screening should not be reused.
CCI
CCI
CCI


TAK-831
Study No. TAK-831-1004
Page 46 of 82
Protocol Incorporating Amendment No. 01
11 April 2017
CONFIDENTIAL
9.1.18 Documentation of Randomization
Only subjects who meet all of the inclusion criteria and none of the exclusion criteria are eligible 
for randomization into the treatment phase.
If the subject is found to be not eligible for randomization, the investigator should record the 
primary reason for failure on the applicable eCRF.
All measurements will be recorded on the source documents and in the eCRF.
9.1.19 C-SSRS
The Baseline/Screening C-SSRS will be administered in this study. The C-SSRS was developed 
by researchers at Columbia University as a tool to help systematically assess suicidal ideation and 
behavior in subjects during participation in a clinical study of centrally-acting drugs [20,21]. The 
C-SSRS is composed of 3 questions addressing suicidal behavior and 5 questions addressing 
suicidal ideation, with subquestions assessing the severity. The tool is administered via interview 
with the subject.
9.2
Monitoring Subject Treatment Compliance
Study drug will be administered while subjects are under observation in the clinic. Following 
administration of the study drug, appropriate mouth and/or hand checks will be performed to 
ensure that the dose is swallowed and noted in the source document. The date and time of each 
dose will be recorded in the source documents and on the eCRFs. An inventory of the study drug 
supplies dispensed will be performed by the site pharmacist or authorized study designee and 
recorded onto the Drug Accountability Log in the subject’s source document records or 
equivalent. The exact time of dosing for consecutive subjects may be staggered to facilitate 
logistics at the site.
9.3
Schedule of Observations and Procedures
The schedule for the study-related procedures to be performed at each visit is shown in 
Appendix A. Assessments should be completed at the designated visit/time points.
9.3.1
Screening
Subjects will be screened within 28 days prior to administration of the first dose of study drug. 
Subjects will be screened in accordance with predefined inclusion and exclusion criteria as 
described in Section 7.0. See Section 9.1.17 for procedures for documenting screen failures.
9.3.2
Study Entrance/Randomization
Eligible subjects will be admitted to the clinic on Day -1 (Check-in) of each period. 
Randomization will occur on Day 1 of Period 1, prior to administration of the first dose of study 
drug.
If the subject has satisfied all of the inclusion criteria and none of the exclusion criteria for study 
entrance, the subject should be randomly assigned to 1 of 2 treatment sequences as described in 


TAK-831
Study No. TAK-831-1004
Page 47 of 82
Protocol Incorporating Amendment No. 01
11 April 2017
CONFIDENTIAL
Section 8.2. In each period, subjects will be administered the dose of study drug in the clinic under 
the supervision of the investigator or designee. 
9.3.3
Treatment Periods 1 and 2
In each period, after administration of the single dose of study drug, subjects will remain confined 
to the clinic until completion of all study-related procedures on Day 3. Subjects will return to the 
clinic for study visits on Days 4, 6, and 8.
9.3.4
Study Exit
The Final Visit will be performed at Study Exit on Day 8 of Period 2. For all subjects receiving 
study drug, the investigator must complete the End-of-Study page of the eCRF.
9.3.5
Early Termination
The reason for discontinuation must be documented in the source document and eCRF. For all 
subjects receiving study drug, the investigator must complete the End-of-Study page of the eCRF.
9.3.6
Follow-up Visit/Telephone Call
The Follow-up Visit will occur by telephone on Study Day 23±2 and will be for the purpose of 
assessing AEs and inquiring about concomitant medications taken since Study Exit. If the subject 
displayed abnormal, clinically significant observations at Study Exit, the subject may be brought 
back into the clinic at the investigator’s discretion for the Follow-up Visit.
9.4
Biological Sample Retention and Destruction
In this study, specimens for genome/gene analysis will be collected as described in Section 9.1.12. 
The genetic material will be extracted, purified, and initially stored at Covance Central Laboratory 
and then preserved and retained at Covance Biorepository for up to but not longer than 15 years or 
as required by applicable law. The sponsor has put into place a system to protect the subjects’ 
personal information to ensure optimal confidentiality and defined standard processes for sample 
and data collection, storage, analysis, and destruction.
The sponsor and researchers working with the sponsor will have access to the samples collected 
and any test results. All samples collected during the study will be stored securely with limited 
access and the sponsor will require anyone who works with the samples to agree to hold the 
research information and any results in confidence.
The sample will be labeled with a unique sample identifier similar to labeling in the main study but 
using a code that is different from the code attached to the health information and other clinical test 
results collected in the study. The sample and data are linked to personal health information with 
code numbers. This link means that the subject may be identified but only indirectly. The code 
numbers will be kept secure by or on behalf of the sponsor.


TAK-831
Study No. TAK-831-1004
Page 48 of 82
Protocol Incorporating Amendment No. 01
11 April 2017
CONFIDENTIAL
Subjects who consented and provided PGx blood samples for DNA analysis can withdraw their 
consent and request disposal of a stored sample at any time. The sponsor should be notified of any 
withdrawal of consent. 
9.5
Blood Volume
Approximate blood volumes to be collected for each subject are shown in Table 9.f. 
Table 9.f
Approximate Blood Volume
Sample Type
Sample
Volume
(mL)
Number of Samples (a)
Total
Volume
(mL) (b)
Screening
Periods 1 and 2
Day
-1
Day
1
Day
2
Day
3
Day
4
Day
5
Day
6
Day
7
Day
8
Clinical 
laboratory (c)
21
1
1 
--
--
1
--
--
--
--
1 (d)
126
PK
4
--
--
10
2
1
1
--
--
--
--
112
PGx DNA
6
--
--
1
--
--
--
--
--
--
--
6
Total Approximate Blood Sampling Volume (mL) (b)
412
-- = no samples collected.
(a) Does not include blood draws at any unscheduled visits.
(b) Total volume for study.
(c) Hematology and serum chemistry.
(d) Applies to Period 2 only.
(e) 
(f) The 168-hour postdose sample for Period 1 may coincide with the 24-hour predose sample on Day -1 of Period 2, in which case 
2 samples will be collected at the same time.
For each subject, the maximum volume of blood collected at any single visit is approximately 
70 mL (Day 1 of each period), and the approximate total volume of blood collected in the study is 
412 mL.
Direct venipuncture is recommended for all blood collections, but if a catheter is used then use the 
saline lock (catheter) for the blood draws without the extra tubing, (eg, BD Insyte Autoguard
#381434 [needle] and ICU Medical, Inc Clave Connector #PM30-2381 or similar). Any other 
method will need to be approved by the sponsor.
CCI
CCI


TAK-831
Study No. TAK-831-1004
Page 49 of 82
Protocol Incorporating Amendment No. 01
11 April 2017
CONFIDENTIAL
10.0
PRETREATMENT EVENTS AND ADVERSE EVENTS
10.1
Definitions
10.1.1 PTEs
A PTE is defined as any untoward medical occurrence in a clinical investigation subject who has 
signed informed consent to participate in a study but prior to administration of any study drug; it 
does not necessarily have to have a causal relationship with study participation.
10.1.2 AEs
An AE is defined as any untoward medical occurrence in a clinical investigation subject 
administered a drug; it does not necessarily have to have a causal relationship with this treatment.
An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant abnormal 
laboratory value), symptom, or disease temporally associated with the use of a drug whether or not 
it is considered related to the drug.
10.1.3 Additional Points to Consider for PTEs and AEs
An untoward finding generally may:

Indicate a new diagnosis or unexpected worsening of a pre-existing condition. (Intermittent 
events for pre-existing conditions or underlying disease should not be considered PTEs or 
AEs.)

Necessitate therapeutic intervention.

Require an invasive diagnostic procedure.

Require discontinuation or a change in dose of study drug or a concomitant medication.

Be considered unfavorable by the investigator for any reason.

PTEs/AEs caused by a study procedure (eg, a bruise after blood draw) should be recorded as a 
PTE/AE.
Diagnoses vs signs and symptoms:

Each event should be recorded to represent a single diagnosis. Accompanying signs (including 
abnormal laboratory values or ECG findings) or symptoms should NOT be recorded as 
additional AEs. If a diagnosis is unknown, sign(s) or symptom(s) should be recorded
appropriately as a PTE(s) or as an AE(s).
Laboratory values and ECG findings:

Changes in laboratory values or ECG findings are only considered to be PTEs or AEs if they 
are judged to be clinically significant (ie, if some action or intervention is required or if the 
investigator judges the change to be beyond the range of normal physiologic fluctuation). A 
laboratory or ECG re-test and/or continued monitoring of an abnormal value or finding are not 


TAK-831
Study No. TAK-831-1004
Page 50 of 82
Protocol Incorporating Amendment No. 01
11 April 2017
CONFIDENTIAL
considered an intervention. In addition, repeated or additional noninvasive testing for 
verification, evaluation, or monitoring of an abnormality is not considered an intervention.

If abnormal laboratory values or ECG findings are the result of pathology for which there is an 
overall diagnosis (eg, increased creatinine in renal failure), the diagnosis only should be 
reported appropriately as a PTE or as an AE.
Pre-existing conditions:

Pre-existing conditions (present at the time of signing of informed consent) are considered 
concurrent medical conditions and should NOT be recorded as PTEs or AEs. Baseline 
evaluations (eg, laboratory tests, ECG, X-rays) should NOT be recorded as PTEs unless 
related to study procedures. However, if the subject experiences a worsening or complication 
of such a concurrent medical condition, the worsening or complication should be recorded 
appropriately as a PTE (worsening or complication occurs before start of study drug) or an AE 
(worsening or complication occurs after start of study drug). Investigators should ensure that 
the event term recorded captures the change in the condition (eg, “worsening of…”).

If a subject has a pre-existing episodic concurrent medical condition (eg, asthma, epilepsy), 
any occurrence of an episode should only be recorded as a PTE/AE if the condition becomes 
more frequent, serious, or severe in nature. Investigators should ensure that the AE term 
recorded captures the change in the condition from Baseline (eg “worsening of…”).

If a subject has a pre-existing degenerative concurrent medical condition (eg, cataracts, 
rheumatoid arthritis), worsening of the condition should only be recorded as a PTE/AE if 
occurring to a greater extent to that which would be expected. Investigators should ensure that 
the AE term recorded captures the change in the condition (eg, “worsening of…”).
Worsening of PTEs or AEs:

If the subject experiences a worsening or complication of a PTE after the start of study drug, 
the worsening or complication should be recorded as an AE. Investigators should ensure that 
the AE term recorded captures the change in the condition (eg, “worsening of…”).

If the subject experiences a worsening or complication of an AE after any change in study 
drug, the worsening or complication should be recorded as a new AE. Investigators should 
ensure that the AE term recorded captures the change in the condition (eg, “worsening of…”).
Changes in intensity of AEs/Serious PTEs:

If the subject experiences changes in intensity of an AE/serious PTE, the event should be 
captured once with the maximum intensity recorded.
Preplanned surgeries or procedures:

Preplanned procedures (surgeries or therapies) that were scheduled prior to signing of 
informed consent are not considered PTEs or AEs. However, if a preplanned procedure is 
performed early (eg, as an emergency) because of a worsening of the pre-existing condition, 


TAK-831
Study No. TAK-831-1004
Page 51 of 82
Protocol Incorporating Amendment No. 01
11 April 2017
CONFIDENTIAL
the worsening of the condition should be recorded as a PTE or an AE. Complications resulting 
from any planned surgery should be reported as AEs.
Elective surgeries or procedures:

Elective procedures performed where there is no change in the subject’s medical condition 
should not be recorded as PTEs or AEs, but should be documented in the subject’s source 
documents. Complications resulting from an elective surgery should be reported as AEs.
Overdose:

Cases of overdose with any medication without manifested side effects are NOT considered 
PTEs or AEs, but instead will be documented on an Overdose page of the eCRF. Any 
manifested side effects will be considered PTEs or AEs and will be recorded on the AE page of 
the eCRF.
10.1.4 SAEs
An SAE is defined as any untoward medical occurrence that at any dose:
1. Results in DEATH.
2. Is LIFE THREATENING.

The term “life threatening” refers to an event in which the subject was at risk of death at the 
time of the event; it does not refer to an event that hypothetically might have caused death 
if it were more severe.
3. Requires inpatient HOSPITALIZATION or prolongation of existing hospitalization.
4. Results in persistent or significant DISABILITY/INCAPACITY.
5. Is a CONGENITAL ANOMALY/BIRTH DEFECT.
6. Is an IMPORTANT MEDICAL EVENT that satisfies any of the following:

May require intervention to prevent items 1 through 5 above.

May expose the subject to danger, even though the event is not immediately life 
threatening or fatal or does not result in hospitalization.

Includes any event or synonym described in the Takeda Medically Significant AE List 
(Table 10.a).


TAK-831
Study No. TAK-831-1004
Page 52 of 82
Protocol Incorporating Amendment No. 01
11 April 2017
CONFIDENTIAL
Table 10.a
Takeda Medically Significant AE List
Term
Acute respiratory failure/acute respiratory distress 
syndrome
Hepatic necrosis
Torsade de pointes/ventricular fibrillation/ventricular 
tachycardia
Acute liver failure
Anaphylactic shock
Malignant hypertension
Acute renal failure
Convulsive seizure
Pulmonary hypertension
Agranulocytosis
Pulmonary fibrosis
Aplastic anemia
Confirmed or suspected endotoxin shock
Toxic epidermal necrolysis/Stevens-Johnson syndrome
Confirmed or suspected transmission of infectious agent 
by a medicinal product
Neuroleptic malignant syndrome/malignant 
hyperthermia
Spontaneous abortion/stillbirth and fetal death
Note: Terms identified on the Medically Significant AE List represent the broad medical concepts to be considered as 
“Important Medical Events” satisfying SAE reporting requirements.
PTEs that fulfill 1 or more of the serious criteria above are also to be considered SAEs and should 
be reported and followed up in the same manner (see Sections 10.2.2 and 10.3).
10.1.5 Intensity of PTEs and AEs
The different categories of intensity (severity) are characterized as follows:
Mild:
The event is transient and easily tolerated by the subject.
Moderate:
The event causes the subject discomfort and interrupts the subject’s usual activities.
Severe:
The event causes considerable interference with the subject’s usual activities.
10.1.6 Relationship of AEs to Study Drug
The relationship of each AE to study drug will be assessed using the following categories:
Related:
An AE that follows a reasonable temporal sequence from administration of a drug (including the 
course after withdrawal of the drug), or for which possible involvement of the drug cannot be 
ruled out, although factors other than the drug, such as underlying diseases, complications, 
concomitant medications, and concurrent treatments, may also be responsible.
Not Related:
An AE that does not follow a reasonable temporal sequence from administration of a drug and/or 
that can reasonably be explained by other factors, such as underlying diseases, complications, 
concomitant medications, and concurrent treatments.
10.1.7 Relationship to Study Procedures
Relationship (causality) to study procedures should be determined for all PTEs and AEs.
The relationship should be assessed as Related if the investigator considers that there is reasonable 
possibility that an event is due to a study procedure. Otherwise, the relationship should be assessed 
as Not Related.


TAK-831
Study No. TAK-831-1004
Page 53 of 82
Protocol Incorporating Amendment No. 01
11 April 2017
CONFIDENTIAL
10.1.8 Start Date
The start date of the AE/PTE is the date that the first signs/symptoms were noted by the subject
and/or investigator.
10.1.9
Stop Date
The stop date of the AE/PTE is the date at which the subject recovered, the event resolved but with 
sequelae, or the subject died.
10.1.10
Frequency
Episodic AEs/PTE (eg, vomiting) or those which occur repeatedly over a period of consecutive 
days are intermittent. All other events are continuous.
10.1.11
Action Concerning Study Drug

Drug withdrawn – a study drug is stopped because of the particular AE.

Dose not changed – the particular AE did not require stopping a study drug.

Unknown – only to be used if it has not been possible to determine what action has been taken.

Not Applicable – a study drug was stopped for a reason other than the particular AE, for 
example, the study has been terminated, the subject died, dosing with study drug was already 
stopped before the onset of the AE.
10.1.12
Outcome

Recovered/resolved – the subject returned to first assessment status with respect to the 
AE/PTE.

Recovering/resolving – the intensity is lowered by 1 or more stages: the diagnosis or 
signs/symptoms has almost disappeared; the abnormal laboratory value improved, but has not 
returned to the normal range or to Baseline; the subject died from a cause other than the 
particular AE/PTE with the condition remaining “recovering/resolving”.

Not recovered/not resolved – there is no change in the diagnosis or signs/symptoms; the 
intensity of the diagnosis, signs/symptoms, or laboratory value on the last day of the observed 
study period has got worse than when it started; is an irreversible congenital anomaly; the 
subject died from another cause with the particular AE/PTE state remaining “Not 
recovered/not resolved”.

Resolved with sequelae – the subject recovered from an acute AE/PTE but was left with 
permanent/significant impairment (eg, recovered from a cardiovascular accident but with 
some persisting paresis).

Fatal – the AEs/PTEs are considered as the cause of death.


TAK-831
Study No. TAK-831-1004
Page 54 of 82
Protocol Incorporating Amendment No. 01
11 April 2017
CONFIDENTIAL

Unknown – the course of the AE/PTE cannot be followed up because of hospital change or 
residence change at the end of the subject’s participation in the study.
10.2
Procedures
10.2.1 Collection and Reporting of AEs
10.2.1.1 PTE and AE Collection Period
Collection of PTEs will commence from the time the subject signs the informed consent to 
participate in the study and continue until the subject is first administered study drug (Day 1 of 
Period 1) or until screen failure. For subjects who discontinue prior to study drug administration, 
PTEs are collected until the subject discontinues study participation.
Collection of AEs will commence from the time that the subject is first administered study drug 
(Day 1 of Period 1). Routine collection of AEs will continue until the Follow-up Phone Call (Study 
Day 23±2).
10.2.1.2 PTE and AE Reporting
At each study visit, the investigator will assess whether any subjective AEs have occurred. A 
neutral question, such as “How have you been feeling since your last visit?” may be asked. 
Subjects may report AEs occurring at any other time during the study. Subjects experiencing a 
serious PTE must be monitored until the symptoms subside and any clinically relevant changes in 
laboratory values have returned to Baseline or there is a satisfactory explanation for the change. 
Nonserious PTEs, related or unrelated to the study procedure, need not to be followed-up for the 
purposes of the protocol.
All subjects experiencing AEs, whether or not considered associated with the use of the study 
drug, must be monitored until the symptoms subside and any clinically relevant changes in 
laboratory values have returned to Baseline or until there is a satisfactory explanation for the 
changes observed. All PTEs and AEs will be documented in the PTE/AE page of the eCRF, 
whether or not the investigator concludes that the event is related to the drug treatment. The 
following information will be documented for each event:
1. Event term.
2. Start and stop date and time.
3. Frequency.
4. Intensity.
5. Investigator’s opinion of the causal relationship between the event and administration of study 
drug (related or not related) (not completed for PTEs).
6. Investigator’s opinion of the causal relationship to study procedure(s), including the details of 
the suspected procedure.
7. Action concerning study drug (not applicable for PTEs).


TAK-831
Study No. TAK-831-1004
Page 55 of 82
Protocol Incorporating Amendment No. 01
11 April 2017
CONFIDENTIAL
8. Outcome of event.
9. Seriousness.
10.2.2 Collection and Reporting of SAEs
When an SAE occurs through the AE collection period it should be reported according to the 
following procedure:
A Takeda SAE form must be completed, in English, and signed by the investigator immediately or 
within 24 hours of first onset or notification of the event. The information should be completed as
fully as possible but contain, at a minimum:

A short description of the event and the reason why the event is categorized as serious.

Subject identification number.

Investigator’s name.

Name of the study drugs.

Causality assessment.
The SAE form should be transmitted within 24 hours to the attention of the contact listed in 
Section 1.1. 
Any SAE spontaneously reported to the investigator following the AE collection period should be 
reported to the sponsor if considered related to study participation.
Reporting of serious PTEs will follow the procedure described for SAEs.
10.2.3 Reporting of Abnormal LFTs
If a subject is noted to have ALT or AST elevated >3×ULN on 2 consecutive occasions, the 
abnormality should be recorded as an AE. In addition, an LFT Increases page of the eCRF must be 
completed providing additional information on relevant recent history, risk factors, clinical signs 
and symptoms, and results of any additional diagnostic tests performed.
If a subject is noted to have ALT or AST >3×ULN and total bilirubin >2×ULN for which an 
alternative etiology has not been identified, the event should be recorded as an SAE and reported 
as per Section 10.2.2. The investigator must contact the Medical Monitor for discussion of the 
relevant subject details and possible alternative etiologies, such as acute viral hepatitis A or B or 
other acute liver disease or medical history/concurrent medical conditions. Follow-up laboratory 
tests as described in Section 9.1.8 must also be performed. In addition, an LFT Increases page of 
the eCRF must be completed and transmitted with the Takeda SAE form (as per Section 10.2.2).
10.3
Follow-up of SAEs
If information is not available at the time of the first report becomes available at a later date, the 
investigator should complete a follow-up SAE form or provide other written documentation and 
fax it immediately within 24 hours of receipt. Copies of any relevant data from the hospital notes 


TAK-831
Study No. TAK-831-1004
Page 56 of 82
Protocol Incorporating Amendment No. 01
11 April 2017
CONFIDENTIAL
(eg, ECGs, laboratory tests, discharge summary, postmortem results) should be sent to the 
addressee, if requested.
All SAEs should be followed up until resolution or permanent outcome of the event. The timelines 
and procedure for follow-up reports are the same as those for the initial report.
10.3.1 Safety Reporting to Investigators, IRBs, and Regulatory Authorities
The sponsor will be responsible for reporting all suspected unexpected serious adverse reactions 
(SUSARs) and any other applicable SAEs to regulatory authorities, investigators, and IRBs, as 
applicable. Relative to the first awareness of the event by/or further provision to the sponsor or 
sponsor’s designee, SUSARs will be submitted to the regulatory authorities as an expedited report 
within 7 days for fatal and life-threatening events and 15 days for other serious events, unless 
otherwise required by national regulations. The sponsor will also prepare an expedited report for 
other safety issues where these might materially alter the current benefit-risk assessment of the 
study drug or that would be sufficient to consider changes in study drug administration or in the 
overall conduct of the trial. The study site also will forward a copy of all expedited reports to his or 
her IRB.


TAK-831
Study No. TAK-831-1004
Page 57 of 82
Protocol Incorporating Amendment No. 01
11 April 2017
CONFIDENTIAL
11.0
STUDY-SPECIFIC COMMITTEES
No steering committee, data safety monitoring committee, or clinical endpoint committee will be 
used in this study.


TAK-831
Study No. TAK-831-1004
Page 58 of 82
Protocol Incorporating Amendment No. 01
11 April 2017
CONFIDENTIAL
12.0
DATA HANDLING AND RECORDKEEPING
The full details of procedures for data handling will be documented in the Data Management Plan. 
AEs, PTEs, medical history, and concurrent medical conditions will be coded using the Medical 
Dictionary for Regulatory Activities (MedDRA). Drugs will be coded using the World Health 
Organization Drug Dictionary.
12.1
eCRFs
Completed eCRFs are required for each subject who signs an informed consent.
The sponsor or its designee will supply study sites with access to eCRFs. The sponsor will make 
arrangements to train appropriate site staff in the use of the eCRF. These forms are used to transmit 
the information collected in the performance of this study to the sponsor and regulatory authorities. 
The eCRFs must be completed in English. Data are transcribed directly onto eCRFs.
After completion of the entry process, computer logic checks will be run to identify items, such as 
inconsistent dates, missing data, and questionable values. Queries may be issued by Takeda 
personnel (or designees) and will be answered by the site.
The principal investigator must review the eCRFs for completeness and accuracy and must sign 
and date the appropriate eCRFs as indicated. Furthermore, the investigator must retain full 
responsibility for the accuracy and authenticity of all data entered on the eCRFs.
The eCRFs will be reviewed for completeness and acceptability at the study site during periodic 
visits by sponsor or its designee. The sponsor or its designee will be permitted to review the 
subject’s medical and hospital records pertinent to the study to ensure accuracy of the eCRFs. The 
completed eCRFs are the sole property of the sponsor and should not be made available in any 
form to third parties, except for authorized representatives of appropriate governmental health or 
regulatory authorities, without written permission of the sponsor.
After lock of the clinical study database or submission of the eCRFs to the sponsor, any change of, 
modification of, or addition to the data on eCRFs should be made by the investigator with use of 
change and modification records of eCRFs (Data Clarification Form) provided by the sponsor. The 
principal investigator must review the Data Clarification Form for completeness and accuracy, and 
must sign and date the form.
12.2
Record Retention
The investigator agrees to keep the records stipulated in Section 12.1 and those documents that 
include (but are not limited to) the study-specific documents, the identification log of all 
participating subjects, medical records, temporary media such as thermal sensitive paper, source 
worksheets, all original signed and dated informed consent forms, subject authorization forms 
regarding the use of personal health information (if separate from the informed consent forms), 
query responses/electronic copy of eCRFs, including the audit trail, and detailed records of drug 
disposition to enable evaluations or audits from regulatory authorities, the sponsor or its designees. 
Any source documentation printed on degradable thermal sensitive paper should be photocopied 
by the site and filed with the original in the subject’s chart to ensure long-term legibility. 


TAK-831
Study No. TAK-831-1004
Page 59 of 82
Protocol Incorporating Amendment No. 01
11 April 2017
CONFIDENTIAL
Furthermore, International Conference on Harmonisation (ICH) E6 Section 4.9.5 requires the 
investigator to retain essential documents specified in ICH E6 (Section 8) until at least 2 years after 
the last approval of a marketing application for a specified drug indication being investigated or, if 
an application is not approved, until at least 2 years after the investigation is discontinued and 
regulatory authorities are notified. In addition, ICH E6 Section 4.9.5 states that the study records 
should be retained until an amount of time specified by applicable regulatory requirements or for a 
time specified in the study site agreement between the investigator and sponsor.
Refer to the study site agreement for the sponsor’s requirements on record retention. The 
investigator should contact and receive written approval from the sponsor before disposing of any 
such documents.


TAK-831
Study No. TAK-831-1004
Page 60 of 82
Protocol Incorporating Amendment No. 01
11 April 2017
CONFIDENTIAL
13.0
STATISTICAL METHODS
13.1
Statistical and Analytical Plans
A statistical analysis plan (SAP) will be prepared and finalized prior to database lock. This 
document will provide further details regarding the definition of analysis variables and analysis 
methodology to address all study objectives.
A targeted data review will be conducted prior to database lock. This review will assess the 
accuracy and completeness of the study database, subject evaluability, and appropriateness of the 
planned statistical methods.
13.1.1 Analysis Sets
Safety Analysis Set
The safety analysis set will consist of all enrolled subjects who received at least 1 dose of study 
drug. Subjects in this analysis set will be used for demographic, other baseline characteristic, and 
safety summaries.
PK Analysis Set
The PK analysis set will consist of subjects from the safety set who have at least 1 measurable 
postdose TAK-831 plasma concentration.
PD Analysis Set
If any subjects are found to have incomplete data, a decision will be made on a case-by-case basis 
as to their inclusion in the analysis; however, all data will be presented in the subject listings.
13.1.2 Analysis of Demographics and Other Baseline Characteristics
Demographic and other baseline characteristic data will be summarized for all enrolled subjects by 
treatment sequence, and overall. Summary statistics (eg, number of subjects, mean, median, SD, 
and range) will be generated for continuous variables (eg, age and weight) and the number and 
percentage of subjects within each category will be presented for categorical variables (eg, sex, 
ethnicity, race, smoking status).
Demographic data and reasons for screen failure will be summarized overall for subjects who are 
screened but not enrolled in the study. Individual demographic data, date of informed consent, and 
reason for screen failure will be listed.
CCI


TAK-831
Study No. TAK-831-1004
Page 61 of 82
Protocol Incorporating Amendment No. 01
11 April 2017
CONFIDENTIAL
13.1.3 PK Analysis
13.1.3.1 TAK-831 Concentrations in Plasma
For each regimen, TAK-831 plasma concentrations will be summarized using descriptive statistics 
(mean, median, SD, %CV, minimum, and maximum) for each scheduled sampling time. 
Individual subject plasma concentration data will be listed.
13.1.3.2 Plasma PK Parameters
For each regimen, TAK-831 plasma PK parameter estimates will be summarized using descriptive 
statistics (N, mean, median, SD, %CV, minimum, and maximum). In addition, geometric means 
will be calculated for Cmax and AUCs. Individual subject plasma PK parameter data will be listed.
Analysis of variance models will be performed on TAK-831 lnCmax and lnAUCs. The model will 
include sequence, period, and regimen as fixed factors and subject-within-sequence as a random 
factor. Pairwise comparisons between the test regimen (Regimen B: fed state) and the reference 
regimen (Regimen A: fasted state) will be made and the 2-sided 90% CIs for the ratio of the central 
values for Cmax and AUCs between regimens (Test: Reference) will be constructed to estimate the 
effect of food on TAK-831 PK.
Additional statistical analyses will be performed as appropriate.
13.1.4 PD Analysis
13.1.4.1
13.1.4.2 Plasma PD Parameters
Additional statistical or PK/PD analyses will be performed as appropriate.
CCI
CCI
CCI


TAK-831
Study No. TAK-831-1004
Page 62 of 82
Protocol Incorporating Amendment No. 01
11 April 2017
CONFIDENTIAL
13.1.5 Safety Analysis
No statistical testing will be performed or inferential statistics will be generated.
13.1.5.1 AEs
All AEs will be coded by system organ class (SOC) and preferred term (PT) using MedDRA. 
TEAEs with onset occurring within 30 days (onset date – last date of dose +1≤30) after the last 
dose of study drug will be included in the summary tables. TEAEs will be summarized by SOC 
and PT with descriptive statistics (N and percentage of subjects). The following summary tables 
will be generated by regimen: all TEAEs, all drug-related TEAEs, relationship of TEAEs to study 
drug (related vs not related), severity of TEAEs, and severity of related TEAEs. Data listings will 
be provided for all AEs including PTE, TEAEs, AEs leading to death, AEs leading to study drug or 
study visit discontinuation, and SAEs.
13.1.5.2 Clinical Laboratory Evaluations
Individual clinical laboratory test data (hematology, chemistry, and urinalysis) will be listed for all 
subjects. Baseline, postdose, and changes from Baseline to postdose data will be summarized by 
regimen for each scheduled time point using descriptive statistics. The Baseline for each regimen 
is defined as the last observation prior to the dose of study drug. Individual clinical laboratory test 
results that meet Takeda’s markedly abnormal criteria (as defined in the SAP) will be listed and 
summarized by regimen. 
13.1.5.3 Vital Signs
Individual vital sign data (oral temperature, respiration rate, blood pressure, and heart rate) will be 
listed for all subjects. Baseline, postdose, and changes from Baseline to postdose data will be 
summarized by regimen for each scheduled time point using descriptive statistics. The Baseline 
for each regimen is defined as the last observation prior to the dose of study drug. Individual vital 
sign results that meet Takeda’s markedly abnormal criteria (as defined in the SAP) will be listed 
and summarized by regimen.
13.1.5.4 ECGs
Individual quantitative 12-lead ECG data will be listed for all subjects. Baseline, postdose, and 
changes from Baseline in quantitative ECG data will be summarized by regimen for each 
scheduled time point using descriptive statistics. The baseline is defined as the last observation 
prior to the dose of study drug. Individual ECG results that meet Takeda’s markedly abnormal 
criteria (as defined in the SAP) will be listed and summarized by regimen.
13.1.5.5 Other Variables
Individual physical examination findings will be listed for all subjects.
13.2
Interim Analysis and Criteria for Early Termination
No interim analysis is planned.


TAK-831
Study No. TAK-831-1004
Page 63 of 82
Protocol Incorporating Amendment No. 01
11 April 2017
CONFIDENTIAL
13.3
Determination of Sample Size
With a sample size of 16 subjects (8 subjects per treatment sequence), allowing for a maximum of 
2 dropouts, a 2-sided 90% CI for the difference in the paired means of the lnCmax will extend 0.23 
from the observed mean. Assuming a point estimate of the food effect of 2 (observed ratio of fed vs 
fasting Cmax=2), which means food increases Cmax by 100%, this should lead to a lower bound of 
the 90% CI of 1.589 (58.9% increase) and an upper bound of the 90% CI of 2.517 (151.7% 
increase) for the ratios of the Cmax central values (fed/fast). In addition, when a central value ratio 
of 1 is observed, the 90% CI should be approximately (-0.79, 1.26). This calculation also assumes 
the intrasubject %CV for Cmax is 37.5%, which is estimated from Study TAK-831-1001 (Part 4).


TAK-831
Study No. TAK-831-1004
Page 64 of 82
Protocol Incorporating Amendment No. 01
11 April 2017
CONFIDENTIAL
14.0
QUALITY CONTROL AND QUALITY ASSURANCE
14.1
Study-Site Monitoring Visits
Monitoring visits to the study site will be made periodically during the study to ensure that all 
aspects of the protocol are followed. Source documents will be reviewed for verification of data 
recorded on the eCRFs. Source documents are defined as original documents, data, and records. 
The investigator and study site guarantee access to source documents by the sponsor or its 
designee (contract research organization) and by the IRB.
All aspects of the study and its documentation will be subject to review by the sponsor or the 
sponsor’s designee, including but not limited to the Investigator’s Binder, study drug, subject 
medical records, informed consent documentation, documentation of subject authorization to use 
personal health information (if separate from the informed consent forms), and review of eCRFs 
and associated source documents. It is important that the investigator and other study personnel are 
available during the monitoring visits and that sufficient time is devoted to the process.
14.2
Protocol Deviations
The investigator should not deviate from the protocol, except where necessary to eliminate an 
immediate hazard to study subjects. Should other unexpected circumstances arise that will require 
deviation from protocol-specified procedures, the investigator should consult with the sponsor or 
designee (and IRB, as required) to determine the appropriate course of action. There will be no 
exemptions (a prospectively approved deviation) from the inclusion or exclusion criteria.
The site should document all protocol deviations in the subject’s source documents, where 
applicable. In the event of a significant deviation, the site should notify the sponsor or its designee 
(and IRB, as required). Significant deviations include, but are not limited to, those that involve 
fraud or misconduct, increase the health risk to the subject, or confound interpretation of primary 
study assessment. A Protocol Deviation Form should be completed by the site and signed by the 
sponsor or designee for any significant deviation from the protocol.
The investigator should document all protocol deviations.
Every attempt will be made to collect each PK and PD blood sample at the designated time point, 
and the actual time of each blood sample will be recorded on the source document and eCRF. 
Blood samples not collected within the window specified for the scheduled sample time should be 
reported to Takeda using the Protocol Deviation Form. Protocol Deviation Forms are to be 
completed for PK/PD samples collected outside of the windows defined in Table 14.a.


TAK-831
Study No. TAK-831-1004
Page 65 of 82
Protocol Incorporating Amendment No. 01
11 April 2017
CONFIDENTIAL
Table 14.a
Windows for PK and PD Blood Sample Collection
Minutes
Nominal Sampling Time
≤30 minutes predose
0 hour
±5
immediately postdose to ≤6 hours
±10
>6 hours to ≤12 hours postdose
±15
>12 hours to ≤24 hours
±30
>24 hours
14.3
Quality Assurance Audits and Regulatory Agency Inspections
The study site also may be subject to quality assurance audits by the sponsor or designees. In this 
circumstance, the sponsor-designated auditor will contact the site in advance to arrange an 
auditing visit. The auditor may ask to visit the facilities where laboratory samples are collected, 
where the medication is stored and prepared, and any other facility used during the study. In 
addition, there is the possibility that this study may be inspected by regulatory agencies, including 
those of foreign governments (eg, the FDA, the United Kingdom Medicines and Healthcare 
products Regulatory Agency [MHRA], the Pharmaceuticals and Medical Devices Agency of 
Japan). If the study site is contacted for an inspection by a regulatory body, the sponsor should be 
notified immediately. The investigator and study site guarantee access for quality assurance 
auditors to all study documents as described in Section 14.1.


TAK-831
Study No. TAK-831-1004
Page 66 of 82
Protocol Incorporating Amendment No. 01
11 April 2017
CONFIDENTIAL
15.0
ETHICAL ASPECTS OF THE STUDY
This study will be conducted with the highest respect for the individual participants (ie, subjects) 
according to the protocol, the ethical principles that have their origin in the Declaration of 
Helsinki, and the ICH Harmonised Tripartite Guideline for GCP. Each investigator will conduct 
the study according to applicable local or regional regulatory requirements and align his or her 
conduct in accordance with the “Responsibilities of the Investigator” that are listed in Appendix B. 
The principles of Helsinki are addressed through the protocol and through appendices containing 
requirements for informed consent and investigator responsibilities.
15.1
IRB Approval
IRBs must be constituted according to the applicable requirements of each participating region. 
The sponsor or designee will require documentation noting all names and titles of members who 
make up the respective IRB. If any member of the IRB has direct participation in this study, 
written notification regarding his or her abstinence from voting must also be obtained. Those 
Americas sites unwilling to provide names and titles of all members because of privacy and 
conflict of interest concerns should instead provide a Federal Wide Assurance Number or 
comparable number assigned by the Department of Health and Human Services.
The sponsor or designee will supply relevant documents for submission to the respective IRB for 
the protocol’s review and approval. This protocol, the Investigator’s Brochure, a copy of the 
informed consent form, and, if applicable, subject recruitment materials and/or advertisements and 
other documents required by all applicable laws and regulations, must be submitted to a central or 
local IRB for approval. The IRB’s written approval of the protocol and subject informed consent 
must be obtained and submitted to the sponsor or designee before commencement of the study 
(ie, before shipment of the sponsor-supplied drug or study-specific screening activity). The IRB 
approval must refer to the study by exact protocol title, number, and version date; identify versions 
of other documents (eg, informed consent form) reviewed; and state the approval date. The 
sponsor will notify the study site once the sponsor has confirmed the adequacy of site regulatory 
documentation and, when applicable, the sponsor has received permission from competent 
authority to begin the study. Until the site receives notification no protocol activities, including 
screening, may occur.
Study sites must adhere to all requirements stipulated by their respective IRB. This may include 
notification to the IRB regarding protocol amendments, updates to the informed consent form, 
recruitment materials intended for viewing by subjects, local safety reporting requirements, 
reports and updates regarding the ongoing review of the study at intervals specified by the 
respective IRB, and submission of the investigator’s final status report to the IRB. All IRB 
approvals and relevant documentation for these items must be provided to the sponsor or its 
designee.
Subject incentives should not exert undue influence for participation. Payments to subjects must 
be approved by the IRB and sponsor.


TAK-831
Study No. TAK-831-1004
Page 67 of 82
Protocol Incorporating Amendment No. 01
11 April 2017
CONFIDENTIAL
15.2
Subject Information, Informed Consent, and Subject Authorization
Written consent documents will embody the elements of informed consent as described in the 
Declaration of Helsinki and the ICH Guidelines for GCP and will be in accordance with all 
applicable laws and regulations. The informed consent form, subject authorization form (if 
applicable), and subject information sheet (if applicable) describe the planned and permitted uses, 
transfers, and disclosures of the subject’s personal and personal health information for purposes of 
conducting the study. The informed consent form and the subject information sheet (if applicable) 
further explain the nature of the study, its objectives, and potential risks and benefits, as well as the 
date informed consent is given. The informed consent form will detail the requirements of the 
participant and the fact that he or she is free to withdraw at any time without giving a reason and 
without prejudice to his or her further medical care.
The investigator is responsible for the preparation, content, and IRB approval of the informed 
consent form and if applicable, the subject authorization form. The informed consent form, subject 
authorization form (if applicable), and subject information sheet (if applicable) must be approved 
by both the IRB and the sponsor prior to use.
The informed consent form, subject authorization form (if applicable), and subject information 
sheet (if applicable) must be written in a language fully comprehensible to the prospective subject. 
It is the responsibility of the investigator to explain the detailed elements of the informed consent 
form, subject authorization form (if applicable), and subject information sheet (if applicable) to the 
subject. Information should be given in both oral and written form whenever possible and in the 
manner deemed appropriate by the IRB. In the event the subject is not capable of rendering 
adequate written informed consent, then the subject’s legally acceptable representative may 
provide such consent for the subject in accordance with applicable laws and regulations.
The subject, or the subject’s legally acceptable representative, must be given ample opportunity to: 
(1) inquire about details of the study and (2) decide whether or not to participate in the study. If the 
subject, or the subject’s legally acceptable representative, determines he or she will participate in 
the study, then the informed consent form and subject authorization form (if applicable) must be 
signed and dated by the subject, or the subject’s legally acceptable representative, at the time of 
consent and prior to the subject entering into the study. The subject or the subject’s legally 
acceptable representative should be instructed to sign using their legal names, not nicknames, 
using blue or black ballpoint ink. The investigator must also sign and date the informed consent 
form and subject authorization (if applicable) at the time of consent and prior to subject entering 
into the study; however, the sponsor may allow a designee of the investigator to sign to the extent 
permitted by applicable law.
Once signed, the original informed consent form, subject authorization form (if applicable), and 
subject information sheet (if applicable) will be stored in the investigator’s site file. The 
investigator must document the date the subject signs the informed consent in the subject’s 
medical record. Copies of the signed informed consent form, the signed subject authorization form 
(if applicable), and subject information sheet (if applicable) shall be given to the subject.


TAK-831
Study No. TAK-831-1004
Page 68 of 82
Protocol Incorporating Amendment No. 01
11 April 2017
CONFIDENTIAL
All revised informed consent forms must be reviewed and signed by relevant subjects or the 
relevant subject’s legally acceptable representative in the same manner as the original informed 
consent. The date the revised consent was obtained should be recorded in the subject’s medical 
record, and the subject should receive a copy of the revised informed consent form.
Subjects who consented and provided a PGx sample for DNA analysis can withdraw their consent 
and request disposal of a stored sample at any time prior to analysis. Notify the sponsor of consent 
withdrawal.
15.3
Subject Confidentiality
The sponsor and designees affirm and uphold the principle of the subject’s right to protection 
against invasion of privacy. Throughout this study, a subject’s source data will only be linked to 
the sponsor’s clinical study database or documentation via a subject identification number. As 
permitted by all applicable laws and regulations, limited subject attributes, such as sex, age, or date 
of birth, and subject initials may be used to verify the subject and accuracy of the subject’s unique 
identification number.
To comply with ICH Guidelines for GCP and to verify compliance with this protocol, the sponsor 
requires the investigator to permit the monitor or the sponsor’s designee, representatives from any 
regulatory authority (eg, FDA, MHRA, Pharmaceuticals and Medical Devices Agency), the 
sponsor’s designated auditors, and the appropriate IRBs to review the subject’s original medical 
records (source data or documents), including, but not limited to, laboratory test result reports, 
ECG reports, admission and discharge summaries for hospital admissions occurring during a 
subject’s study participation, and autopsy reports. Access to a subject’s original medical records 
requires the specific authorization of the subject as part of the informed consent process (see 
Section 15.2).
Copies of any subject source documents that are provided to the sponsor must have certain 
personally identifiable information removed (ie, subject name, address, and other identifier fields 
not collected on the subject’s eCRF).
15.4
Publication, Disclosure, and Clinical Trial Registration Policy
15.4.1 Publication and Disclosure
The investigator is obliged to provide the sponsor with complete test results and all data derived by 
the investigator from the study. During and after the study, only the sponsor may make study 
information available to other study investigators or to regulatory agencies, except as required by 
law or regulation. Except as otherwise allowable in the study site agreement, any public disclosure 
(including publicly accessible websites) related to the protocol or study results, other than study 
recruitment materials and/or advertisements, is the sole responsibility of the sponsor.
The sponsor may publish any data and information from the study (including data and information 
generated by the investigator) without the consent of the investigator. Manuscript authorship for 
any peer-reviewed publication will appropriately reflect contributions to the production and 
review of the document. All publications and presentations must be prepared in accordance with 


TAK-831
Study No. TAK-831-1004
Page 69 of 82
Protocol Incorporating Amendment No. 01
11 April 2017
CONFIDENTIAL
this section and the study site agreement. In the event of any discrepancy between the protocol and 
the study site agreement, the study site agreement will prevail.
15.4.2 Clinical Trial Registration
In order to ensure that information on clinical trials reaches the public in a timely manner and to 
comply with applicable laws, regulations, and guidance, Takeda will, at a minimum register all 
interventional clinical trials it sponsors anywhere in the world on ClinicalTrials.gov and/or other 
publicly accessible websites before start of study, as defined in Takeda Policy/Standard. Takeda
contact information, along with investigator’s city, state (for Americas investigators), country, and 
recruiting status will be registered and available for public viewing.
For some registries, Takeda will assist callers in locating trial sites closest to their homes by 
providing the investigator name, address, and phone number to the callers requesting trial 
information. Once subjects receive investigator contact information, they may call the site 
requesting enrollment into the trial. The investigative sites are encouraged to handle the trial 
inquiries according to their established subject screening process. If the caller asks additional 
questions beyond the topic of trial enrollment, they should be referred to the sponsor.
Any investigator who objects to the sponsor providing this information to callers must provide the 
sponsor with a written notice requesting that their information not be listed on the registry site.
15.4.3 Clinical Trial Results Disclosure
Takeda will post the results of clinical trials on ClinicalTrials.gov or other publicly accessible 
websites, as required by Takeda Policy/Standard, applicable laws, and/or regulations.
15.5
Insurance and Compensation for Injury
Each subject in the study must be insured in accordance with the regulations applicable to the site 
where the subject is participating. If a local underwriter is required, then the sponsor or sponsor’s 
designee will obtain clinical study insurance against the risk of injury to study subjects. Refer to 
the study site agreement regarding the sponsor’s policy on subject compensation and treatment for 
injury. If the investigator has questions regarding this policy, he or she should contact the sponsor 
or sponsor’s designee.


TAK-831
Study No. TAK-831-1004
Page 70 of 82
Protocol Incorporating Amendment No. 01
11 April 2017
CONFIDENTIAL
16.0
REFERENCES
1. Fredericks CM. Disorders of the cerebellum and its connections. In: Fredericks C, Saladin LK, 
editors. Pathophysiology of the Motor Systems: Principles and Clinical Presentations. 
Philadelphia, PA: F. A. Davis; 1996.
2. Wilson CL, Fahey MC, Corben LA, Collins VR, Churchyard AJ, Lamont PJ, et al. Quality of 
life in Friedreich ataxia: what clinical, social and demographic factors are important? Eur J 
Neurol 2007;14(9):1040-7.
3. Pandolfo M. Friedreich ataxia: the clinical picture. J Neurol 2009;256 Suppl 1:3-8.
4. Santos R, Lefevre S, Sliwa D, Seguin A, Camadro JM, Lesuisse E. Friedreich ataxia: 
molecular mechanisms, redox considerations, and therapeutic opportunities. Antioxid Redox 
Signal 2010;13(5):651-90.
5. Campuzano V, Montermini L, Molto MD, Pianese L, Cossee M, Cavalcanti F, et al. 
Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat 
expansion. Science 1996;271(5254):1423-7.
6. Koeppen AH. Friedreich's ataxia: pathology, pathogenesis, and molecular genetics. J Neurol 
Sci 2011;303(1-2):1-12.
7. Campuzano V, Montermini L, Lutz Y, Cova L, Hindelang C, Jiralerspong S, et al. Frataxin is 
reduced in Friedreich ataxia patients and is associated with mitochondrial membranes. Hum 
Mol Genet 1997;6(11):1771-80.
8. Sacchi S. D-Serine metabolism: new insights into the modulation of D-amino acid oxidase 
activity. Biochem Soc Trans 2013;41(6):1551-6.
9. Saigoh K, Matsui K, Takahashi K, Nishikawa T, Wada K. The stereo-specific effect of 
D-serine ethylester and the D-cycloserine in ataxic mutant mice. Brain Res 1998;808(1):42-7.
10. Koeppen AH, Mazurkiewicz JE. Friedreich ataxia: neuropathology revised. J Neuropathol Exp 
Neurol 2013;72(2):78-90.
11. Friedreich’s Ataxia Research Alliance. Research Pipeline. Updated 2016. Accessed 01 
November 2016. Available at: http://www.curefa.org/pipeline.
12. Perlman SL. A review of Friedreich ataxia clinical trial results. J Child Neurol 
2012;27(9):1217-22.
13. Akbar U, Ashizawa T. Ataxia. Neurol Clin 2015;33(1):225-48.
14. Kakegawa W, Miyoshi Y, Hamase K, Matsuda S, Matsuda K, Kohda K, et al. D-serine 
regulates cerebellar LTD and motor coordination through the delta2 glutamate receptor. Nat 
Neurosci 2011;14(5):603-11.
15. Horiike K, Tojo H, Arai R, Nozaki M, Maeda T. D-amino-acid oxidase is confined to the lower 
brain stem and cerebellum in rat brain: regional differentiation of astrocytes. Brain Res 
1994;652(2):297-303.


TAK-831
Study No. TAK-831-1004
Page 71 of 82
Protocol Incorporating Amendment No. 01
11 April 2017
CONFIDENTIAL
16. Ichise M, Toyama H, Innis RB, Carson RE. Strategies to improve neuroreceptor parameter 
estimation by linear regression analysis. J Cereb Blood Flow Metab 2002;22(10):1271-81.
17. Guidance for Industry: Food-Effect Bioavailability and Fed Bioequivalence Studies. US Dept 
of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation 
and Research. December 2002.
18. Guideline on the Investigation of Bioequivalence. European Medicines Agency, Committee 
for Medicinal Products for Human Use. 20 January 2010. Publication No. 
CPMP/EWP/QWP/1401/98 Rev. 1.
19. Guideline on the Investigation of Drug Interactions. European Medicines Agency, Committee 
for Human Medicinal Products. 21 June 2012. Publication No. CPMP/EWP/560/95/Rev. 1 
Final.
20. Posner K, Oquendo MA, Gould M, Stanley B, Davies M. Columbia Classification Algorithm 
of Suicide Assessment (C-CASA): classification of suicidal events in the FDA's pediatric 
suicidal risk analysis of antidepressants. Am J Psychiatry 2007;164(7):1035-43.
21. Posner K, Melvin GA, Stanley B, Oquendo MA, Gould M. Factors in the assessment of 
suicidality in youth. CNS Spectr 2007;12(2):156-62.


TAK-831
Study No. TAK-831-1004
Page 72 of 82
Protocol Incorporating Amendment No. 01
11 April 2017
Appendix A
Schedule of Study Procedures
Period Day
Screening
Treatment Period 1 
Treatment Period 2
ET (a)
Follow-up (b)
-28 to -2
-1
(Period 1 
Check-in)
1
2
3
4
6
8/-1
(Period 2 
Check-in) 
1
2
3
4
6
8 
(Study 
Exit)
Study Day
-28 to -2
-1
1
2
3
4
6
8
9
10
11
12
14
16
23 (±2)
Informed consent
X
Inclusion/exclusion criteria
X
X
Demographics, medical history
X
Medication history
X
Physical examination
X
X
X
X
Vital signs (c)
X
X
X (d)
X
X
X
X
X
X (d)
X
X
X
X
X
X
Weight, height, BMI (e)
X
X
X
X
Concomitant medications (f)
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Concurrent medical conditions
X
X
Clinical laboratory tests (g)
X
X
X (h)
X (i)
X (h)
X
X
HBsAg, anti-HCV, HIV
X
FSH (j)
X
Pregnancy test (hCG) (k)
X
X
X
X
Urine drug screen
X
X
X
C-SSRS
X
X
X
X
ECG
X
X
X (l)
X
X (l)
X
X
DNA sample collection (m)
X
PK blood collection (n)
X
X
X
X
X
X
X
X
Dispense study drug
X
X
Confinement
X
X
X
X
X
X
X
X
PTE assessment (p)
X
X
X
AE assessment (q)
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Footnotes for Appendix A are on the next page.
CCI


TAK-831
Study No. TAK-831-1004
Page 73 of 82
Protocol Incorporating Amendment No. 01
11 April 2017
CONFIDENTIAL
Footnotes for Appendix A:
ET=Early Termination.
(a) Procedures to be performed for subjects who prematurely discontinue the study. 
(b) The Follow-up Visit will occur (14 days after the last dose of study drug) by telephone unless abnormal, clinically significant findings were observed at Study Exit. In these cases, 
subjects will be brought back into the clinic for re-evaluation at the investigator’s discretion.
(c) Vital signs will include oral body temperature, respiratory rate, blood pressure, and heart rate (beats per minute). Blood pressure and heart rate will be measured in 2 positions: 
after 5 minutes supine and then after 1 and 3 minutes standing.
(d) Vital signs will be measured at predose (within 50 minutes before dosing) and at 1, 4, and 12 hours postdose.
(e) Height and BMI only will be collected at Screening.
(f) All concomitant medications taken from Screening and throughout the study will be recorded.
(g) Hematology, serum chemistry, and urinalysis.
(h) Blood and urine samples for clinical laboratory tests will be collected on rising.
(i) Only 1 blood sample will be collected on this day that will serve as the Period 2 Day -1 sample.
(j) FSH levels will be measured for female subjects when menopause is suspected and subject is not surgically sterile.
(k) Pregnancy test will be performed for female subjects only.
(l) 12-lead ECG will be performed at 1 hour, 2 hours, and 4 hours postdose.
(m) One blood sample (6 mL) will be collected for DNA analysis before dosing on Day 1 of Period 1. 
(n) Blood samples (4 mL) for PK analysis will be collected at predose (within 15 minutes of dosing) and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 8, 12, 24, 36, 48, and 72 hours postdose in each 
period.
(o) Blood samples (6 mL) for PD analysis (D-serine and L-serine) will be collected on Day -1 at 24, 20, 16, and 12 hours before the Day 1 dose and on Day 1 at predose (within 15 
minutes prior to dosing) and at 4, 8, 12, 24, 36, 48, 72, 120, and 168 hours postdose in each period. The 168-hour postdose sample for Period 1 may coincide with the 24-hour predose 
sample on Day -1 of Period 2, in which case 2 samples will be collected at the same time.
(p) PTEs will be collected from the time the subject signs the informed consent until the subject is first administered study drug (Day 1 of Period 1) or until screen failure. 
(q) AEs will be collected from the time the subject is first administered study drug (Day 1 of Period 1) until the Follow-up Phone Call (Study Day 23 [±2]).


TAK-831
Study No. TAK-831-1004
Page 74 of 82
Protocol Incorporating Amendment No. 01
11 April 2017
CONFIDENTIAL
Appendix B
Responsibilities of the Investigator
Clinical research studies sponsored by the sponsor are subject to ICH GCP and all the applicable 
local laws and regulations. The responsibilities imposed on investigators by the FDA are 
summarized in the “Statement of Investigator” (Form FDA 1572), which must be completed and 
signed before the investigator may participate in this study.
The investigator agrees to assume the following responsibilities by signing a Form FDA 1572:
1. Conduct the study in accordance with the protocol.
2. Personally conduct or supervise the staff who will assist in the protocol.
3. Ensure that study-related procedures, including study-specific (nonroutine/nonstandard panel) 
screening assessments are NOT performed on potential subjects, prior to the receipt of written 
approval from relevant governing bodies/authorities.
4. Ensure that all colleagues and employees assisting in the conduct of the study are informed of 
these obligations.
5. Secure prior approval of the study and any changes by an appropriate IRB that conform to 
21 Code of Federal Regulations (CFR) Part 56, ICH, and local regulatory requirements.
6. Ensure that the IRB will be responsible for initial review, continuing review, and approval of 
the protocol. Promptly report to the IRB all changes in research activity and all anticipated 
risks to subjects. Make at least yearly reports on the progress of the study to the IRB, and issue 
a final report within 3 months of study completion.
7. Ensure that requirements for informed consent, as outlined in 21 CFR Part 50, ICH, and local 
regulations, are met.
8. Obtain valid informed consent from each subject who participates in the study, and document 
the date of consent in the subject’s medical chart. Valid informed consent is the most current 
version approved by the IRB. Each informed consent form should contain a subject 
authorization section that describes the uses and disclosures of a subject’s personal 
information (including personal health information) that will take place in connection with the 
study. If an informed consent form does not include such a subject authorization, then the 
investigator must obtain a separate subject authorization form from each subject or the 
subject’s legally acceptable representative.
9. Prepare and maintain adequate case histories of all persons entered into the study, including 
eCRFs, hospital records, laboratory results, etc, and maintain these data for a minimum of 
2 years following notification by the sponsor that all investigations have been discontinued or 
that the regulatory authority has approved the marketing application. The investigator should 
contact and receive written approval from the sponsor before disposing of any such 
documents.
10. Allow possible inspection and copying by the regulatory authority of GCP-specified essential 
documents.


TAK-831
Study No. TAK-831-1004
Page 75 of 82
Protocol Incorporating Amendment No. 01
11 April 2017
CONFIDENTIAL
11. Maintain current records of the receipt, administration, and disposition of sponsor-supplied 
drugs, and return all unused sponsor-supplied drugs to the sponsor.
12. Report adverse reactions to the sponsor promptly. In the event of an SAE, notify the sponsor 
within 24 hours.


TAK-831
Study No. TAK-831-1004
Page 76 of 82
Protocol Incorporating Amendment No. 01
11 April 2017
CONFIDENTIAL
Appendix C
Elements of the Subject Informed Consent
In seeking informed consent, the following information shall be provided to each subject:
1. A statement that the study involves research.
2. An explanation of the purposes of the research.
3. The expected duration of the subject’s participation.
4. A description of the procedures to be followed, including invasive procedures.
5. The identification of any procedures that are experimental.
6. The estimated number of subjects involved in the study.
7. A description of the subject’s responsibilities.
8. A description of the conduct of the study.
9. A statement describing the treatment(s) and the probability for random assignment to each 
treatment.
10. A description of the possible side effects of the treatment that the subject may receive.
11. A description of any reasonably foreseeable risks or discomforts to the subject and, when 
applicable, to an embryo, fetus, or nursing infant.
12. A description of any benefits to the subject or to others that reasonably may be expected from 
the research. When there is no intended clinical benefit to the subject, the subject should be 
made aware of this.
13. Disclosures of appropriate alternative procedures or courses of treatment, if any, that might be 
advantageous to the subject and their important potential risks and benefits.
14. A statement describing the extent to which confidentiality of records identifying the subject 
will be maintained, and a note of the possibility that regulatory agencies, auditor(s), IRB, and 
the monitor may inspect the records. By signing a written informed consent form, the subject 
or the subject’s legally acceptable representative is authorizing such access.
15. For research involving more than minimal risk, an explanation as to whether any compensation 
and an explanation as to whether any medical treatments are available if injury occurs and, if 
so, what they consist of or where further information may be obtained.
16. The anticipated prorated payment(s), if any, to the subject for participating in the study.
17. The anticipated expenses, if any, to the subject for participating in the study.
18. An explanation of whom to contact for answers to pertinent questions about the research 
(investigator), subject’s rights, and IRB and whom to contact in the event of a research-related 
injury to the subject.
19. A statement that participation is voluntary, that refusal to participate will involve no penalty or 
loss of benefits to which the subject otherwise is entitled, and that the subject may discontinue 


TAK-831
Study No. TAK-831-1004
Page 77 of 82
Protocol Incorporating Amendment No. 01
11 April 2017
CONFIDENTIAL
participation at any time without penalty or loss of benefits to which the subject is otherwise 
entitled.
20. The consequences of a subject’s decision to withdraw from the research and procedures for 
orderly termination of participation by the subject.
21. A statement that the subject or the subject’s legally acceptable representative will be informed 
in a timely manner if information becomes available that may be relevant to the subject’s 
willingness to continue participation in the study.
22. A statement that results of PGx analysis will not be disclosed to an individual, unless 
prevailing laws require the sponsor to do so.
23. The foreseeable circumstances or reasons under which the subject’s participation in the study 
may be terminated.
24. A written subject authorization (either contained within the informed consent form or provided 
as a separate document) describing to the subject the contemplated and permissible uses and 
disclosures of the subject’s personal information (including personal health information) for 
purposes of conducting the study. The subject authorization must contain the following 
statements regarding the uses and disclosures of the subject’s personal information:
a) that personal information (including personal health information) may be processed by or 
transferred to other parties in other countries for clinical research and safety reporting 
purposes, including, without limitation, to the following: (1) Takeda, its affiliates, and 
licensing partners; (2) business partners assisting Takeda, its affiliates, and licensing 
partners; (3) regulatory agencies and other health authorities; and (4) IRBs;
b) it is possible that personal information (including personal health information) may be 
processed and transferred to countries that do not have data protection laws that offer 
subjects the same level of protection as the data protection laws within this country; 
however, Takeda will make every effort to keep your personal information confidential, 
and your name will not be disclosed outside the clinic unless required by law;
c) that personal information (including personal health information) may be added to 
Takeda’s research databases for purposes of developing a better understanding of the 
safety and effectiveness of the study drug, studying other therapies for patients, developing 
a better understanding of disease, and improving the efficiency of future clinical studies;
d) that subjects agree not to restrict the use and disclosure of their personal information 
(including personal health information) upon withdrawal from the study to the extent that 
the restricted use or disclosure of such information may impact the scientific integrity of 
the research; and
e) that the subject’s identity will remain confidential in the event that study results are 
published.


TAK-831
Study No. TAK-831-1004
Page 78 of 82
Protocol Incorporating Amendment No. 01
11 April 2017
CONFIDENTIAL
25. Male subjects must use highly effective contraception (as defined in the informed consent) 
from Screening, throughout the duration of the study, and for 95 days after the last dose of 
study drug.
26. A statement that clinical trial information from this trial will be publicly disclosed in a publicly 
accessible website, such as ClinicalTrials.gov.


TAK-831
Study No. TAK-831-1004
Page 79 of 82
Protocol Incorporating Amendment No. 01
11 April 2017
CONFIDENTIAL
Appendix D
Investigator Consent to Use of Personal Information
Takeda will collect and retain personal information of the investigator, including his or her name, 
address, and other personally identifiable information. In addition, the investigator’s personal 
information may be transferred to other parties located in countries throughout the world (eg, the 
United Kingdom, United States, and Japan), including the following:

Takeda, its affiliates, and licensing partners.

Business partners assisting Takeda, its affiliates, and licensing partners.

Regulatory agencies and other health authorities.

IRBs.
The investigator’s personal information may be retained, processed, and transferred by Takeda 
and these other parties for research purposes including the following:

Assessment of the suitability of the investigator for the study and/or other clinical studies.

Management, monitoring, inspection, and audit of the study.

Analysis, review, and verification of the study results.

Safety reporting and pharmacovigilance relating to the study.

Preparation and submission of regulatory filings, correspondence, and communications to 
regulatory agencies relating to the study.

Preparation and submission of regulatory filings, correspondence, and communications to 
regulatory agencies relating to other medications used in other clinical studies that may contain 
the same chemical compound present in the study drug.

Inspections and investigations by regulatory authorities relating to the study.

Self-inspection and internal audit within Takeda, its affiliates, and licensing partners.

Archiving and audit of study records.

Posting investigator site contact information, study details, and results on publicly accessible 
clinical trial registries, databases, and websites.
The investigator’s personal information may be transferred to other countries that do not have data 
protection laws that offer the same level of protection as data protection laws in the investigator’s 
own country.
The investigator acknowledges and consents to the use of his or her personal information by 
Takeda and other parties for the purposes described above.


TAK-831
Study No. TAK-831-1004
Page 80 of 82
Protocol Incorporating Amendment No. 01
11 April 2017
CONFIDENTIAL
Appendix E
Detailed Description of Amendments to Text
Change 1. Addition of investigator’s clinical judgment as criterion for withdrawing subject due to 
liver function test abnormalities.
The primary change occurs in Section 7.5 Criteria for Discontinuation or Withdrawal of a Subject
Initial 
wording:
1. Pretreatment event (PTE) or AE. The subject has experienced a PTE or AE that 
requires early termination because continued participation imposes an 
unacceptable risk to the subject’s health or the subject is unwilling to continue 
because of the PTE or AE.

Liver Function Test (LFT) Abnormalities
Study drug should be discontinued immediately with appropriate clinical 
follow-up (including repeat laboratory tests, until a subject’s laboratory profile 
has returned to normal/baseline status, see Section 9.1.8), if the following 
circumstances occur at any time during study drug treatment:
–
ALT or AST >8×ULN, or
–
ALT or AST >5×ULN and persists for >2 weeks, or
–
ALT or AST >3×ULN in conjunction with elevated total bilirubin 
>2×ULN or INR >1.5, or
–
ALT or AST >3×ULN with appearance of fatigue, nausea, vomiting, right 
upper quadrant pain or tenderness, fever, rash, and/or eosinophilia (>5%).


TAK-831
Study No. TAK-831-1004
Page 81 of 82
Protocol Incorporating Amendment No. 01
11 April 2017
CONFIDENTIAL
Amended 
or new 
wording:
1. Pretreatment event (PTE) or AE. The subject has experienced a PTE or AE that 
requires early termination because continued participation imposes an 
unacceptable risk to the subject’s health or the subject is unwilling to continue 
because of the PTE or AE.

Liver Function Test (LFT) Abnormalities
Study drug should be discontinued immediately with appropriate clinical 
follow-up (including repeat laboratory tests, until a subject’s laboratory profile 
has returned to normal/baseline status, see Section 9.1.8), if the following 
circumstances occur at any time during study drug treatment:
–
ALT or AST >8×ULN, or
–
ALT or AST >5×ULN and persists for >2 weeks or based on clinical 
judgment of the investigator, or
–
ALT or AST >3×ULN in conjunction with elevated total bilirubin 
>2×ULN or INR >1.5, or
–
ALT or AST >3×ULN with appearance of fatigue, nausea, vomiting, right 
upper quadrant pain or tenderness, fever, rash, and/or eosinophilia (>5%).
Rationale for Change:
Clarifies that investigator may use clinical judgment when determining if abnormalities (even of 
shorter duration) make it necessary to withdraw subject from the study.


TAK-831
Study No. TAK-831-1004
Page 82 of 82
Protocol Incorporating Amendment No. 01
11 April 2017
CONFIDENTIAL
Change 2. Correction of inconsistences in the description of contraception requirements.
The primary change occurs in Section 9.1.9.1 Male Subjects and Their Female Partners
Initial 
wording:
From signing of informed consent, throughout the duration of the study, and for 95 
days after the last dose of study drug, nonsterilized** male subjects who are sexually 
active with a female partner of childbearing potential* must use barrier contraception
(eg, condom with spermicidal cream or jelly). In addition, they must be advised not to 
donate sperm during this period. Women of childbearing potential who are partners of 
male subjects are also advised to use additional contraception as shown in the list
containing highly effective contraception below. 
Amended 
or new 
wording:
From signing of informed consent, throughout the duration of the study, and for 95 
days after the last dose of study drug, nonsterilized** male subjects who are sexually 
active with a female partner of childbearing potential* must use barrier contraception
(eg, condom with spermicidal cream or jelly). In addition, they must be advised not to 
donate sperm during this period. Women of childbearing potential who are partners of 
male subjects are also advised to use additional contraception as shown in the list
containing highly effective contraception below. If the female partner has been 
using 1 of the hormonal contraceptives methods listed below for >3 months, 
condom use is advised but not mandated.
Rationale for Change:
Clarifies the intended requirements. 
Change 3. Addition of extra ECG timepoints.
The primary change occurs in Appendix A, Schedule of Study Procedures
Initial 
wording:
Footnotes for Appendix A:
…
(l) 12-lead ECG will be performed at 2 hours postdose.
Amended 
or new 
wording:
Footnotes for Appendix A:
…
(l) 12-lead ECG will be performed at 1 hour, 2 hours, and 4 hours postdose.
Rationale for Change:
Additional ECG measurements at 1 and 4 hours after dosing will extend these measurements to the 
expected time of Cmax of the TAK-831 tablet.




䢢
䢢
䢢
䢢
䢢
䢢
䢢
䢢
(/(&7521,&6,*1$785(6
Signed by 
Meaning of Signature 
Server Date 
(dd-MMM-yyyy HH:mm ‘UTC’) 




 
 
 




 
 
 




 
 
 




 
 
 




 
 
 




 
 
 




 
 
 




 
 
 




 
 
 




 
 
 




 
 
 




 
 
 




 
 
 




 
 
 




 
 
 




 
 
 




 
 
 




 
 
 




 
 
 





GE
䣃䣯䣧䣰䣦䣯䣧䣰䣶䢢䢲䢳䢢䣶䣱䢢䣃䣰䢢䣑䣲䣧䣰䢯䣎䣣䣤䣧䣮䢮䢢䣕䣫䣰䣩䣮䣧䢯䣆䣱䣵䣧䢮䢢䢴䢯䣒䣧䣴䣫䣱䣦䢢䣕䣧䣳䣷䣧䣰䣶䣫䣣䣮䢢䣆䣧䣵䣫䣩䣰䢢䣒䣪䣣䣵䣧䢢䢳䢢䣕䣶䣷䣦䣻䢢䣶䣱䢢䣇䣸䣣䣮䣷䣣䣶䣧䢢䣶䣪䣧
䣇䣨䣨䣧䣥䣶䢢䣱䣨䢢䣈䣱䣱䣦䢢䣱䣰䢢䣶䣪䣧䢢䣒䣪䣣䣴䣯䣣䣥䣱䣭䣫䣰䣧䣶䣫䣥䣵䢢䣱䣨䢢䢢䣖䣃䣍䢯䢺䢵䢳䢢䣈䣱䣴䣯䣷䣮䣣䣶䣫䣱䣰䢢䣖䢴䢢䣫䣰䢢䣊䣧䣣䣮䣶䣪䣻䢢䣕䣷䣤䣬䣧䣥䣶䣵
&OLQLFDO$SSURYDO
$SU87&
&OLQLFDO3KDUPDFRORJ\$SSURYDO
$SU87&
%LRVWDWLVWLFV$SSURYDO
$SU87&
&OLQLFDO93$SSURYDO
$SU87&
PPD

SAP_001.pdf: 
This may include, but is not limited to, redaction of the following: 

Named persons or organizations associated with the study.

•
Other information as needed to protect confidentiality of Takeda or partners, personal
information, or to otherwise protect the integrity of the clinical study.
 SAP Approve Date: 09 June 2017
Certain information within this Statistical Analysis Plan has been redacted (ie, specific content 
is masked irreversibly from view with a black bar) to protect either personally identifiable 
information or company confidential information. 
Proprietary information, such as scales or coding systems, which are considered confidential
information under prior agreements with license holder.
Title: A Randomized, Open-Label, Single-Dose, 2-Period, Crossover Design, Phase 1 Study to 
Evaluate the Effect of Food on the Pharmacokinetics of TAK-831 T2 Tablet Formulation in 
Healthy Subjects
NCT Number: NCT03101293


TAKEDA DEVELOPMENT CENTER
STATISTICAL ANALYSIS PLAN
STUDY NUMBER: TAK-831-1004
A Randomized, Open-Label, Single-Dose, 2-Period, Crossover Design, Phase 1 Study to 
Evaluate the Effect of Food on the Pharmacokinetics of TAK-831 T2 Tablet Formulation in 
Healthy Subjects
Phase 1, Food Effect Study of TAK-831
PHASE 1
Version: Final V1.0
Date: 09 June 2017
Prepared by:
Based on:
Protocol Version: Amendment 01
Protocol Date: 11 April 2017
CONFIDENTIAL PROPERTY OF TAKEDA
This document is a confidential communication of Takeda. Acceptance of this document 
constitutes the agreement by the recipient that no information contained herein will be published 
or disclosed without written authorization from Takeda.
PPD


TAK-831_1004
Page 2 of 21
Statistical Analysis Plan Final
09 June 2017
CONFIDENTIAL
1.1
Approval Signatures
Study Title:
A Randomized, Open-Label, Single-Dose, 2-Period, Crossover Design, 
Phase 1 Study to Evaluate the Effect of Food on the Pharmacokinetics of 
TAK-831 T2 Tablet Formulation in Healthy Subjects
Takeda Approvals:
Date
Date
Date
Date
Date
PPD
PPD
PPD
PPD
PPD


TAK-831_1004
Page 3 of 21
Statistical Analysis Plan Final
09 June 2017
CONFIDENTIAL
2.0
TABLE OF CONTENTS
1.0
TITLE PAGE ..................................................................................................................1
1.1
Approval Signatures ..................................................................................................2
2.0
TABLE OF CONTENTS.................................................................................................3
3.0
LIST OF ABBREVIATIONS..........................................................................................5
4.0
OBJECTIVES .................................................................................................................6
4.1
Primary Objective......................................................................................................6
4.2
Secondary Objective..................................................................................................6
4.3
Exploratory Objective................................................................................................6
4.4
Study Design .............................................................................................................6
5.0
ANALYSIS ENDPOINTS...............................................................................................8
5.1
Primary Endpoints .....................................................................................................8
5.2
Secondary Endpoints .................................................................................................8
5.3
Exploratory Endpoints ...............................................................................................8
6.0
DETERMINATION OF SAMPLE SIZE.........................................................................9
7.0
METHODS OF ANALYSIS AND PRESENTATION...................................................10
7.1
General Principles....................................................................................................10
7.1.1
Missing Data......................................................................................................10
7.1.2
Derived Datasets and Variables..........................................................................10
7.1.3
Definition of Study Days and Baseline...............................................................11
7.2
Analysis Sets ...........................................................................................................11
7.3
Disposition of Subjects ............................................................................................11
7.4
Demographic and Baseline Characteristics...............................................................11
7.5
Medical History and Concurrent Medical Conditions...............................................12
7.6
Medication History and Concomitant Medications...................................................12
7.7
Study Drug Exposure and Compliance.....................................................................12
7.8
Efficacy Analysis.....................................................................................................12
7.9
Pharmacokinetic Analysis........................................................................................12
7.9.1
Plasma Concentrations.......................................................................................12
7.9.2
Plasma Pharmacokinetic Parameters ..................................................................13
7.10
Pharmacodynamic Analysis .....................................................................................13
7.10.1 D-Serine and L-Serine Plasma Concentrations ...................................................13
7.10.2 Plasma PD Parameters .......................................................................................14
7.11
Other Outcomes.......................................................................................................15
7.12
Safety Analysis........................................................................................................15


TAK-831_1004
Page 4 of 21
Statistical Analysis Plan Final
09 June 2017
CONFIDENTIAL
7.12.1 Adverse Events ..................................................................................................15
7.12.2 Clinical Laboratory Evaluations .........................................................................15
7.12.3 Vital Signs .........................................................................................................16
7.12.4 12-Lead ECGs ...................................................................................................16
7.12
Interim Analysis ......................................................................................................17
7.13
Changes in the Statistical Analysis Plan...................................................................17
8.0
REFERENCES..............................................................................................................18
LIST OF IN-TEXT FIGURES
Figure 4.a
Study Treatment Sequences .................................................................................6
LIST OF APPENDICES
Appendix A
Criteria for Identification of Markedly Abnormal Laboratory Values .................19
Appendix B
Criteria for Markedly Abnormal Values for Vital Signs......................................20
Appendix C
Criteria for Markedly Abnormal Values for Electrocardiograms.........................21


TAK-831_1004
Page 5 of 21
Statistical Analysis Plan Final
09 June 2017
CONFIDENTIAL
3.0
LIST OF ABBREVIATIONS
%CV
percent coefficient of variation
ADaM
Analysis Data Model
AE
adverse event
ANCOVA
analysis of covariance
ANOVA
analysis of variance
AUC∞
area under the plasma concentration-time curve from time 0 to infinity, calculated as 
AUC∞=AUClast+Clast/λz
AUClast
area under the plasma concentration-time curve from time 0 to last quantifiable 
concentration
AUEClast
area under the effect-time curve from time 0 to the last scheduled post dose time point
(last = 168 h)
BLQ
below the limit of quantification
BMI
body mass index
CI
confidence interval
CL/F
apparent clearance after extravascular administration, calculated as CL/F =Dose/AUC∞
after a single dose
Cmax
maximum observed plasma concentration
ECG
electrocardiogram
eCRF
electronic case report forms
Emax
maximum observed effect
LS
least squares
MAV
markedly abnormal value
MedDRA
Medical Dictionary for Regulatory Activities
N
number of subjects
PD
pharmacodynamic(s)
PK
pharmacokinetic(s)
PT
preferred term
PTE
pretreatment event
QTcF
QT interval with Fridericia correction method
Residual Area
postulated area: (AUC∞- AUCt)/AUC∞
t1/2z
terminal elimination half-life, calculated as ln(2)/λz
TEAE
treatment-emergent adverse event
time to Emax
time to reach maximum observed effect
tmax
time to reach Cmax
Vz/F 
apparent volume of distribution during the terminal phase after extravascular 
administration, calculated as (CL/F)/λz
WHO Drug
World Health Organization Drug Dictionary
λz
terminal elimination rate constant, calculated as the negative of the slope of the log-
linear regression of the natural logarithm concentration-time curve during the terminal 
phase


TAK-831_1004
Page 6 of 21
Statistical Analysis Plan Final
09 June 2017
CONFIDENTIAL
4.0
OBJECTIVES
4.1
Primary Objective
!
To determine the PK of a single oral dose of TAK-831 400 mg in the fasted state and to 
estimate the effect of food on the PK of a single oral dose of TAK-831 400 mg when 
administered as the T2 tablet formulation in healthy subjects.
4.2
Secondary Objective
!
To evaluate the safety and tolerability of a single oral dose of TAK-831 400 mg in healthy 
subjects in the fed and fasted states.
4.3
Exploratory Objective
4.4
Study Design
TAK-831-1004 is a phase 1, randomized, open-label, single-dose, 2-period crossover study 
designed to characterize the PK of TAK-831 400 mg and assess the effect of food on the 
bioavailability of TAK-831 400 mg, when administered as four 100 mg oral tablets of the T2 
formulation in healthy male and female adult subjects. At Check-in (Day -1) of Period 1, 
16 healthy male and female subjects, aged 18 to 55 years, inclusive, who meet the study entry 
criteria will be enrolled in the study. On Day 1 of Period 1, eligible subjects will be randomly 
assigned in a 1:1 ratio to 1 of 2 treatment sequences, which will define the order in which they 
will receive the TAK-831 regimens in Periods 1 and 2 (Figure 4.a). Dosing between periods will 
be separated by a washout interval of ≥7 days. 
Figure 4.a
Study Treatment Sequences
Treatment 
Sequence
Number Of 
Subjects
Regimen
Period 1
Period 2
1
8
A
B
2
8
B
A
Regimen A=a single oral dose of 4 TAK-831 100 mg tablets (T2 formulation; total dose 400 mg) administered on 
Day 1 with water;
Regimen B=a single oral dose of 4 TAK-831 100 mg tablets (T2 formulation; total dose 400 mg) administered on 
Day 1, 15 minutes after starting ingestion of Ensure Plus. For both regimens, subjects will fast for ≥10 hours 
overnight before dosing.
The study will include a Screening Period (Days -28 to -2), 2 treatment periods, and a Follow-up 
Phone Call (14±2 days after last dose of study drug). In each period, subjects will be admitted to 
the clinic on Day -1 (Check-in) and will remain confined to the clinic until completion of study
procedures on the morning of Day 3. Subjects will return to the clinic for study assessments on 
Days 4, 6, and 8 in each period. Subjects will receive a single dose of TAK-831 on Day 1 of each 
CCI


TAK-831_1004
Page 7 of 21
Statistical Analysis Plan Final
09 June 2017
CONFIDENTIAL
period. Blood samples will be collected over 72 hours post dose to measure plasma 
concentrations of TAK-831 for PK assessments in each period. 
 
. Safety will be evaluated throughout the 
study.
A schematic of the study design is shown in Figure 4.a. A schedule of study procedures is 
provided in Appendix A of the protocol. 
CCI
CCI
CCI


TAK-831_1004
Page 8 of 21
Statistical Analysis Plan Final
09 June 2017
CONFIDENTIAL
5.0
ANALYSIS ENDPOINTS
5.1
Primary Endpoints
The following PK parameters of TAK-831 derived for each regimen:
!
Maximum observed plasma concentration (Cmax).
!
Area under the plasma concentration-time curve from time 0 to time of the last quantifiable 
concentration (AUClast).
!
Area under the plasma concentration-time curve from time 0 to infinity (AUC∞).
5.2
Secondary Endpoints
!
Percentage of subjects who experience at least 1 TEAE.
5.3
Exploratory Endpoints
The following additional safety endpoints:
!
Percentage of subjects who meet the markedly abnormal criteria for clinical laboratory tests 
at least once post dose.
!
Percentage of subjects who meet the markedly abnormal criteria for vital sign measurements 
at least once post dose.
!
Percentage of subjects who meet the markedly abnormal criteria for 12-lead ECG parameters 
at least once post dose.
The following PK parameters for TAK-831 for each regimen:
!
tmax.
!
t1/2z.
!
CL/F.
!
Vz/F.
CCI


TAK-831_1004
Page 9 of 21
Statistical Analysis Plan Final
09 June 2017
CONFIDENTIAL
6.0
DETERMINATION OF SAMPLE SIZE
With a sample size of 16 subjects (8 subjects per treatment sequence), allowing for a maximum 
of 2 dropouts, a 2-sided 90% CI for the difference in the paired means of the lnCmax will extend 
0.23 from the observed mean. Assuming a point estimate of the food effect of 2 (observed ratio 
of fed vs. fasting Cmax=2), which means food increases Cmax by 100%, this should lead to a lower 
bound of the 90% CI of 1.589 (58.9% increase) and an upper bound of the 90% CI of 2.517 
(151.7% increase) for the ratios of the Cmax central values (fed/fast). In addition, when a central 
value ratio of 1 is observed, the 90% CI should be approximately (-0.79, 1.26). This calculation 
also assumes the intrasubject %CV for Cmax is 37.5%, which is estimated from Study 
TAK-831-1001 (Part 4).


TAK-831_1004
Page 10 of 21
Statistical Analysis Plan Final
09 June 2017
CONFIDENTIAL
7.0
METHODS OF ANALYSIS AND PRESENTATION
7.1
General Principles
This Statistical Analysis Plan (SAP) was developed based on International Conference on 
Harmonization E3 [2] and E9 [3] Guidelines. This SAP should be read in conjunction with the 
study protocol and electronic case report forms (eCRFs). This version of the SAP was developed 
using the information provided in Protocol TAK-831-1004, dated 11 April 2017 [1].
All study-related raw data, including derived data, will be presented in data listings. Continuous 
data will be summarized using: number of subjects (N), mean, standard deviation (SD), median, 
minimum, and maximum, where appropriate. Where indicated, %CV and geometric mean will 
also be included in the summary of continuous data. Categorical data will be summarized using 
the number and percentage of subjects for each category where appropriate.
7.1.1
Missing Data
There will be no imputation of incomplete or missing data. Decisions regarding inclusion or 
exclusion of data from an analysis for subjects who are noncompliant with the dose schedule, or 
who have incomplete data, will be made on a case-by-case basis, but the data will be presented in 
data listings regardless. 
Plasma concentrations that are below the limit of quantification (BLQ) will be given a value of 
0 in the summarization of concentrations and derivation of the PK parameters. These values will 
be flagged in the data listings, and deviations from this convention may be considered on a 
case-by-case basis as deemed appropriate.
7.1.2
Derived Datasets and Variables
Derived datasets will be generated according to CDISC guidance documents: Analysis Data 
Model (ADaM) Implementation Guide, Version 1.1 (12 Feb 2016); ADaM Data Structure for 
Adverse Event Analysis, Version 1.0 (10 May 2012). 
CCI


TAK-831_1004
Page 11 of 21
Statistical Analysis Plan Final
09 June 2017
CONFIDENTIAL
7.1.3
Definition of Study Days and Baseline
For safety labs, vital signs and ECGs, Baseline is defined as the last nonmissing measurement 
prior to first dose of study drug for the respective period. For all other safety endpoints, Baseline 
is defined as the last nonmissing measurement prior to the first dose of study drug in Period 1. 
Study day prior to the first dose of study drug will be calculated as: date of assessment/event –
date of first dose of study drug; study day on or after the date of first dose of study drug will be 
calculated as: date of assessment/event – date of first dose of study drug + 1.
7.2
Analysis Sets
Safety Analysis Set
The safety analysis set will consist of all randomized subjects 
who received at least 1 dose of study drug. Subjects in this 
analysis set will be used for demographic, other baseline 
characteristic, and safety summaries.
PK Analysis Set
PD Analysis Set
The PK analysis set will consist of subjects from the safety set 
who have at least 1 measurable post dose TAK-831 plasma 
concentration.
7.3
Disposition of Subjects
The number and percentage of subjects who complete study drugs and study visits, and those 
who prematurely discontinue study drugs and study visits will be summarized for each sequence 
and overall. In addition, the number and percentage of subjects will be summarized for reasons 
of study drug discontinuation and study visit discontinuation for each sequence and overall. 
Subjects’ study completion data, including reasons for premature termination, will be listed. 
The number and percentage of subjects comprising each analysis set will be summarized for each 
sequence and overall. 
7.4
Demographic and Baseline Characteristics
Demographic and other baseline characteristic data will be listed and summarized for all enrolled 
subjects by treatment sequence and overall. Summary statistics (eg, N, mean, median, SD, 
minimum and maximum) will be generated for continuous variables (eg, age and weight), and 
the number and percentage of subjects within each category will be presented for categorical 
variables (eg, sex, ethnicity, and race). 
Demographic data and reasons for screen failure will be summarized overall for subjects who are 
screened but not enrolled in the study. Individual demographic characteristics, date of informed 
consent and reason for screen failure will also be presented in the data listings.
CCI


TAK-831_1004
Page 12 of 21
Statistical Analysis Plan Final
09 June 2017
CONFIDENTIAL
7.5
Medical History and Concurrent Medical Conditions
Medical history includes any significant conditions that stopped at or prior to signing of 
informed consent. Concurrent medical conditions are those significant ongoing conditions that 
are present at signing of informed consent.
Medical history and concurrent medical condition verbatim reported terms will be coded using 
the Medical Dictionary for Regulatory Activities (MedDRA). No summary statistics for medical 
history and concurrent medical conditions will be provided. All medical history and concurrent 
medical conditions will be listed.
7.6
Medication History and Concomitant Medications
Medication history information obtained includes any medication stopped at or within 28 days 
prior to signing of informed consent. Medications used from signing of informed consent 
through the end of study will be considered as concomitant medications.
Medication history and concomitant medications will be coded using World Health Organization 
Drug Dictionary (WHO Drug). No summary statistics for medication history and concomitant 
medications will be provided. All medication history and concomitant medications data will be 
listed.
7.7
Study Drug Exposure and Compliance
The date and time of each dose for each subject will be reported in the data listing. Daily meals 
during confinement in each period will be reported in the data listing. Summary statistics for 
TAK-831 plasma concentrations and pharmacokinetic parameters will be provided. No summary 
statistics for the extent of exposure to study drug or compliance calculations will be performed 
for this study.
7.8
Efficacy Analysis
Not applicable.
7.9
Pharmacokinetic Analysis
7.9.1
Plasma Concentrations 
Serial blood samples for determination of plasma concentrations of TAK-831 will be collected 
according to the table below:
Analyte
Matrix
Dosing Day
(Period 1 and 2)
Scheduled Time (hours)
TAK-831
Plasma
1
Pre-dose (0 hour, within 15 minutes prior to 
dose) and 0.25, 0.5, 1, 1.5, 2, 3, 4, 8, 12, 24, 
36, 48 and 72 hours post dose


TAK-831_1004
Page 13 of 21
Statistical Analysis Plan Final
09 June 2017
CONFIDENTIAL
The concentration of TAK-831 in plasma will be summarized by regimen at each scheduled 
sampling time using descriptive statistics (N, mean, median, SD, %CV, minimum, and 
maximum). Individual plasma concentration data versus time will be presented in a data listing.
7.9.2
Plasma Pharmacokinetic Parameters
The pharmacokinetic (PK) parameters of TAK-831 will be determined from the 
concentration-time profiles for all evaluable subjects. Actual sampling times, rather than 
scheduled sampling times, will be used in all computations involving sampling times. The 
following PK parameters will be calculated from the plasma concentration values of TAK-831 
using non-compartmental analysis using Phoenix WinNonLin (version 6.3 or higher): AUClast, 
AUC∞, Cmax, CL/F, λz, t1/2z, tmax and Vz/F.
Additional parameters may be calculated if necessary.
For each regimen, descriptive statistics (N, mean, median, SD, %CV, minimum, and maximum) 
will be used to summarize TAK-831 plasma PK parameters. In addition, geometric means will 
be calculated for Cmax and AUCs. Individual subject plasma PK parameter data will be listed.
Statistical inference to estimate the food effect on TAK-831 PK will be performed using an 
analysis of variance (ANOVA) model on TAK-831 lnCmax and lnAUCs. The models will include 
sequence, period, and regimen as fixed factors and subject-within-sequence as a random factor. 
Difference between the test regimen (Regimen B: fed state) and the reference regimen (Regimen 
A: fasted state) will be calculated using the least square (LS) means and 90% C.Is. 
To evaluate the effect of food on TAK-831 PK, the central value ratios and the 2-sided 90% CIs 
for the ratio of the central values for Cmax and AUCs between the two regimens will be obtained 
as the antilog of the difference of the least squares (LS) means on a natural logarithm scale, and 
the 90% CIs will be obtained by taking the antilog of the 90% CI for the difference between the 
LS means on the natural logarithmic scale. 
Alternative statistical analyses will be used if deemed appropriate.
7.10
Pharmacodynamic Analysis
7.10.1 D-Serine and L-Serine Plasma Concentrations
CCI


TAK-831_1004
Page 14 of 21
Statistical Analysis Plan Final
09 June 2017
CONFIDENTIAL
7.10.2 Plasma PD Parameters
Alternative statistical or PK/PD analyses will be used if deemed appropriate.
CCI
CCI
CCI


TAK-831_1004
Page 15 of 21
Statistical Analysis Plan Final
09 June 2017
CONFIDENTIAL
7.11
Other Outcomes
Not applicable. 
7.12
Safety Analysis
All safety summary tables will be presented by regimen for all subjects in the safety analysis set. 
No statistical testing will be performed or inferential statistics will be generated. All CRF 
collected data will be listed, including: CSSRS, Investigational Drug Overdoses, Physical 
Examinations, pharmacogenomics sampling times and Telephone Follow-Up Assessments.
7.12.1 Adverse Events
All AEs will be coded by system organ class (SOC) and preferred term (PT) using MedDRA. 
TEAEs with onset occurring after first dose of study drug and within 30 days (onset date – last 
date of dose +1≤30) after the last dose of study drug be included in the summary tables. 
The TEAE summary tables will include numbers and percentages of subjects experiencing at 
least one TEAE by SOC and PT and will be tabulated by regimen The TEAE will also be 
summarized for all subjects in the overview assessment. The following is a list of TEAE 
summary tables to be generated: 

Overview of TEAEs.

TEAEs by SOC and PT

Subject Mappings for TEAEs.

TEAEs by PT.

Most Frequent TEAEs by PT.

Most Frequent Non-Serious TEAEs by PT.

Drug-Related TEAEs by SOC and PT.

Relationship of TEAEs to Study Drug by SOC and PT (related vs not related). 

Intensity of TEAEs by SOC and PT.

Intensity of Drug-Related TEAEs by SOC and PT. 
Additional AE summary tables may be added as appropriate. 
Data listings will be provided for all AEs including PTE, TEAEs, and AEs leading to death, AEs 
leading to study drug or study visit discontinuation, SAEs and signs and symptoms of AEs 
related to increased liver function tests.
7.12.2 Clinical Laboratory Evaluations
Clinical safety laboratory tests include clinical chemistry, hematology, and urinalysis. The 
samples for these tests are collected at Screening, Check-in Period 1, Day 3 Period 1, Check-in 


TAK-831_1004
Page 16 of 21
Statistical Analysis Plan Final
09 June 2017
CONFIDENTIAL
Period 2 (Day -1 of Period 2; also Day 8 of Period 1), and Day 3 Period 2 and Study Exit (Day 8 
of Period 2 or Early Termination). 
Descriptive statistics (N, mean, median, SD, minimum and maximum) of clinical laboratory tests 
will be summarized for baseline, post dose (Days 3 and 8), and change from baseline to post
dose by regimen. The Baseline for each regimen is defined as the last observation prior to the 
dose of study drug in the corresponding period. Only the scheduled measurements will be 
included in the summary. No statistical tests will be performed. 
Individual results for clinical laboratory test will be evaluated against the Takeda predefined 
laboratory markedly abnormal values (MAV) criteria (Appendix A) using the result and criteria 
in SI units. All subjects with at least 1 post dose laboratory result that meets the MAV criteria 
will be presented in a data listing. The number and percentage of subjects with at least 1 post 
dose markedly abnormal laboratory test result will also be summarized by regimen. Subjects who 
meet the MAV criteria will be mapped to their respective qualifying laboratory result. All post 
dose clinical lab MAV results, including scheduled and unscheduled measurements will be 
included in the MAV summaries. 
All clinical laboratory data will be presented in both SI and conventional units in data listings. 
7.12.3 Vital Signs
Vital sign measurements include body temperature, respiratory rate, blood pressure, and heart 
rate (beats per minute). Vital signs are measured at Screening, Check-in Period 1, Day 1 (within 
50 minutes before dosing and at 1, 4, and 12 hours post dose), 2, 3, 4 and 6 of each period, 
Check-in Period 2 (also Day 8 of Period 1) and at Study Exit (Day 8 of Period 2 or Early 
Termination).
Descriptive statistics (N, mean, median, SD, minimum and maximum) of vital signs in each 
position (supine, standing and orthostatic change for blood pressure and heart rate) will be 
summarized for baseline, post dose, and change from baseline to post dose by regimen. The 
Baseline for each regimen is defined as the last observation prior to the dose of study drug in the 
corresponding period. Only the scheduled measurements will be included in the summary. No 
statistical tests will be performed. 
All individual vital signs that meet Takeda’s predefined criteria for MAVs (Appendix B) will be 
listed. The number and percentage of subjects with at least 1 post dose markedly abnormal vital 
sign measurement will be summarized by regimen. Subjects who meet the MAV criteria will be 
mapped to their respective qualifying vital sign result. All post dose MAV vital signs, including 
both scheduled and unscheduled measurements, will be included in the MAV summaries.
All clinical laboratory data will be presented in both SI and conventional units in data listings. 
7.12.4 12-Lead ECGs
A standard 12-lead ECG will be recorded. The investigator (or a qualified observer at the 
investigational site) will manually interpret the ECG using 1 of the following categories: within 
normal limits, abnormal but not clinically significant, or abnormal and clinically significant. The 


TAK-831_1004
Page 17 of 21
Statistical Analysis Plan Final
09 June 2017
CONFIDENTIAL
following parameters will be calculated automatically by the ECG machine: heart rate, RR 
interval, PR interval, QT interval, QRS interval, and QT interval with Bazett and Frederica 
correction method (QTcB and QTcF, respectively). ECGs will be obtained at Screening, 
Check-in Period 1, Day 1 (1, 2 and 4 hours post dose) of Period 1 and 2, Check-in Period 2 
(Day 8 of Period 1) and Study Exit (Day 8 of Period 2 or Early Termination).
Descriptive statistics of the continuous ECG parameters will be summarized for baseline, post 
dose, and change from baseline at each post dose time point by regimen. The Baseline for each 
regimen is defined as the last observation prior to the dose of study drug in the corresponding 
period. Only the ECGs collected at the scheduled visits or time points will be included in the 
summary. No statistical tests will be performed for the observed ECG parameters.
All individual ECGs that meet Takeda’s predefined criteria for MAVs (Appendix B) will be 
listed. The number and percentage of subjects with at least 1 post dose markedly abnormal ECG 
measurement will be summarized by regimen. Subjects who meet the MAV criteria will be 
mapped to their respective qualifying ECG result. All post dose MAV ECG parameters, 
including both scheduled and unscheduled measurements, will be included in the MAV 
summaries.
Individual subject ECGs will be presented in a data listing. 
7.12
Interim Analysis
Not applicable.
7.13
Changes in the Statistical Analysis Plan
Not applicable.


TAK-831_1004
Page 18 of 21
Statistical Analysis Plan Final
09 June 2017
CONFIDENTIAL
8.0
REFERENCES
1. Protocol: A Randomized, Open-Label, Single-Dose, 2-Period, Crossover Design, Phase 1 
Study to Evaluate the Effect of Food on the Pharmacokinetics of TAK-831 T2 Tablet 
Formulation in Healthy Subjects Amendment 01, 11 April 2017.
2. Guideline on Structure and Content of Clinical Study Reports, International Conference on 
Harmonisation, Section ICH E3, 1996.
3. Guideline on Statistical Principles for Clinical Trials, International Conference on 
Harmonisation, Section ICH E9, 1998.


TAK-831_1004
Page 19 of 21
Statistical Analysis Plan Final
09 June 2017
CONFIDENTIAL
Appendix A
Criteria for Identification of Markedly Abnormal Laboratory Values
Hematology—Criteria for Markedly Abnormal Values
Parameter
Unit
Low Abnormal
High Abnormal
Hemoglobin
Both 
<0.8 × LLN
>1.2 × ULN
Hematocrit
Both
<0.8 × LLN
>1.2 × ULN
RBC count 
Both
<0.8 × LLN 
>1.2 × ULN
WBC count 
Both 
<0.5 x LLN
>1.5 x ULN
Platelet count
Conventional
<75 x 103/L
>600 x 103/L
SI
<75 x 109/L
>600 x 109/L
LLN=lower limit of normal, RBC=red blood cell, ULN=upper limit of normal, WBC=white blood cell. 
Serum Chemistry—Criteria for Markedly Abnormal Values
Parameter
Unit 
Low Abnormal
High Abnormal
ALT
Both
--
>3x ULN
AST
Both
--
>3x ULN
GGT
Both
--
>3x ULN
Alkaline phosphatase
Both
--
>3x ULN
Total bilirubin
Conventional
--
>2.0 mg/dL
SI
--
>34.2 mol/L
Albumin
Conventional 
<2.5 g/dL
--
SI 
<25 g/L
--
Total protein
Both
<0.8x LLN
>1.2x ULN
Creatinine
Conventional 
--
>2.0 mg/dL
SI
>177 mol/L
Blood urea nitrogen
Conventional 
>30 mg/dL
SI
>10.7 mmol/L
Sodium
Conventional
<130 mEq/L
>150 mEq/L
SI
<130 mmol/L
>150 mmol/L
Potassium
Conventional
<3.0 mEq/L
>6.0 mEq/L
SI
<3.0 mmol/L
>6.0 mmol/L
CPK
Both
--
>5x ULN
Glucose
Conventional
<50 mg/dL
>350 mg/dL
SI
<2.8 mmol/L
>19.4 mmol/L
ALT=alanine aminotransferase, AST=aspartate aminotransferase, CPK=creatine phosphokinase, GGT=-glutamyl 
transferase, LLN=lower limit of normal, ULN=upper limit of normal.


TAK-831_1004
Page 20 of 21
Statistical Analysis Plan Final
09 June 2017
CONFIDENTIAL
Appendix B
Criteria for Markedly Abnormal Values for Vital Signs
Parameter
Unit
Lower Criteria 
Upper Criteria
Pulse
bpm
<50 
>120
Systolic blood pressure
mm Hg
<85 
>180 
Diastolic blood pressure
mm Hg
<50 
>110
Body temperature
oC
<35.6
>37.7
Criteria for Identification of Markedly Abnormal Orthostatic Changes
Parameter
Criteria
Orthostatic Hypotension
(Orthostatic Systolic Blood Pressure <-20 mm Hg OR
Orthostatic Diastolic Blood Pressure <-10 mm Hg) AND Heart 
Rate Increase >20 beats/min
Note: Orthostatic measurement = standing vital measurement – supine vital measurement.


TAK-831_1004
Page 21 of 21
Statistical Analysis Plan Final
09 June 2017
CONFIDENTIAL
Appendix C
Criteria for Markedly Abnormal Values for Electrocardiograms
Parameter
Lower Criteria 
Upper Criteria
Heart rate
<50 beats per minute
>120 beats per minute
PR
≤80 milliseconds
≥200 milliseconds
QTcB Interval
≤300 milliseconds
≥500 milliseconds OR 
≥30 milliseconds change from baseline and
≥450 milliseconds
QTcF Interval
≤300 milliseconds
≥500 milliseconds OR 
≥30 milliseconds change from baseline and
≥450 milliseconds
QRS
≤80 milliseconds
≥180 milliseconds




䢢
䢢
䢢
䢢
䢢
䢢
䢢
䢢
(/(&7521,&6,*1$785(6
Signed by 
Meaning of Signature 
Server Date 
(dd-MMM-yyyy HH:mm ‘UTC’) 




 
 
 




 
 
 




 
 
 




 
 
 




 
 
 




 
 
 




 
 
 




 
 
 




 
 
 




 
 
 




 
 
 




 
 
 




 
 
 




 
 
 




 
 
 




 
 
 




 
 
 




 
 
 




 
 
 





GFED
䣖䣃䣍䢯䢺䢵䢳䢯䢳䢲䢲䢶䢢䣕䣶䣣䣶䣫䣵䣶䣫䣥䣣䣮䢢䣃䣰䣣䣮䣻䣵䣫䣵䢢䣒䣮䣣䣰
%LRVWDWLVWLFV$SSURYDO
-XQ87&
&OLQLFDO$SSURYDO
-XQ87&
&OLQLFDO3KDUPDFRORJ\$SSURYDO
-XQ87&
&OLQLFDO93$SSURYDO
-XQ87&
3KDUPDFRYLJLODQFH$SSURYDO
-XQ87&
PPD